🏷

Classifications

ICD-O Morphology

Harrison's Part

◆

Subtypes

12

lineage

B-cell acute lymphoblastic leukemia

Precursor B-lineage ALL. Current WHO and ICC frameworks further classify most cases by ploidy, recurrent rearrangement, sequence alteration, or expression-defined genetic subtype.

Ph-positive
Ph-like
KMT2A-rearranged
ETV6-RUNX1
TCF3-PBX1
High hyperdiploidy
Hypodiploidy
iAMP21
PAX5-altered

Show evidence (1 reference)

PMID:36422706 SUPPORT Other

"The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes both revisions to subtypes previously outlined in the 2016 WHO classification and several newly described entities."

The ICC establishes B-ALL and T-ALL as lineage families with revised and newly defined subtypes.

T-cell acute lymphoblastic leukemia

Precursor T-lineage ALL characterized by recurrent disruption of T-cell transcriptional programs, NOTCH1 signaling, cell-cycle control, and other stage-associated pathways.

ETP-ALL

Show evidence (1 reference)

PMID:28671688 SUPPORT Human Clinical

"Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has not been carried out."

Integrated sequencing defines the major recurrent pathway classes in human T-ALL.

T-lineage developmental subtype

Early T-cell precursor acute lymphoblastic leukemia

An early T-precursor subtype with a distinct immunophenotypic and genomic profile, including enrichment for lesions also seen in stem or myeloid programs. It is classified within the T-ALL family rather than treated as a B-lineage genetic subtype.

Show evidence (1 reference)

PMID:36422706 SUPPORT Other

"T-ALL classification is also updated to incorporate BCL11B-activating rearrangements into early T-precursor (ETP) ALL taxonomy."

The ICC explicitly places early T-precursor ALL in the updated T-ALL taxonomy.

recurrent fusion

BCR::ABL1-positive / Philadelphia chromosome-positive B-ALL MONDO:0035940

B-ALL with t(9;22) and BCR::ABL1. The constitutively active ABL1 kinase creates a targetable signaling dependency and makes this subtype distinct from expression-similar BCR::ABL1-like disease.

Show evidence (1 reference)

PMID:41251904 SUPPORT Human Clinical

"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR::ABL1 fusion gene resulting from the translocation t(9;22)."

This defines the BCR::ABL1 fusion lesion of Ph-positive ALL.

ETV6::RUNX1 B-ALL MONDO:0035942

B-ALL with t(12;21) and ETV6::RUNX1, a childhood-enriched recurrent fusion with a distinctive relapse pattern.

Show evidence (1 reference)

PMID:28418909 SUPPORT Human Clinical

"ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL)."

This supports ETV6::RUNX1 as a recurrent childhood ALL fusion subtype.

TCF3::PBX1 B-ALL

B-ALL with t(1;19) and TCF3::PBX1. Its molecular identity is retained even though outcomes depend on treatment context.

Show evidence (1 reference)

PMID:39261601 SUPPORT Human Clinical

"Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short median time-to-relapse (12.5-18 months) and poor OS post-relapse (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%)."

The cohort treats TCF3::PBX1 as a recurrent genetic subtype.

kinase-activated expression subtype

BCR::ABL1-like / Philadelphia chromosome-like B-ALL

B-ALL with a BCR::ABL1-like expression profile but no BCR::ABL1 fusion. Diverse ABL-class, JAK-STAT, cytokine-receptor, and other kinase lesions require molecular characterization rather than inference from the label.

Show evidence (1 reference)

PMID:23523389 SUPPORT Other

"Ten to 12 percent of B-ALL cases exhibit a gene expression profile similar to that of BCR-ABL1 ALL but are BCR-ABL1-negative, commonly show IKZF1 alteration, and have a poor outcome"

The review directly defines the BCR::ABL1-like expression subtype and separates it from BCR::ABL1-positive disease.

recurrent rearrangement

KMT2A-rearranged B-ALL MONDO:0035941

B-ALL with a KMT2A rearrangement and one of several fusion partners. It is prominent in infant ALL and has clinically important relapse behavior.

Show evidence (1 reference)

PMID:39261601 SUPPORT Human Clinical

"Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short median time-to-relapse (12.5-18 months) and poor OS post-relapse (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%)."

The COG cohort identifies KMT2A rearrangement as a clinically distinct recurrent subtype.

aneuploid subtype

High-hyperdiploid B-ALL MONDO:0035943

B-ALL defined by high hyperdiploidy and recurrent whole-chromosome gains.

Show evidence (1 reference)

PMID:35732829 SUPPORT Other

"B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy"

WHO-HAEM5 lists high-hyperdiploid B-lymphoblastic leukemia/lymphoma as a classified entity.

Hypodiploid B-ALL MONDO:0035944

B-ALL with a hypodiploid chromosome complement, encompassing biologically distinct near-haploid and low-hypodiploid groups.

Show evidence (1 reference)

PMID:36422706 SUPPORT Other

"B-ALL classification is modified to further subclassify BCR::ABL1-positive B-ALL and hypodiploid B-ALL."

The ICC explicitly recognizes and further subdivides hypodiploid B-ALL.

focal amplification subtype

B-ALL with intrachromosomal amplification of chromosome 21

B-ALL with intrachromosomal amplification of chromosome 21. Accurate genomic detection matters because unusual amplification patterns may not satisfy a simple FISH rule.

Show evidence (1 reference)

PMID:35771717 SUPPORT Human Clinical

"Acute lymphoblastic leukemia (B-ALL) with intrachromosomal amplification of chromosome 21 (iAMP21-ALL) represents a recurrent high-risk cytogenetic abnormality and accurate identification is critical for appropriate clinical management."

This cohort supports iAMP21 as a recurrent cytogenetic B-ALL subtype.

transcription-factor altered subtype

PAX5-altered / PAX5alt B-ALL

A B-ALL expression subtype enriched for diverse PAX5 rearrangements, mutations, and focal or intragenic amplifications rather than one uniform rearrangement.

Show evidence (1 reference)

PMID:30643249 SUPPORT Human Clinical

"One, PAX5alt (7.4%), has diverse PAX5 alterations (rearrangements, intragenic amplifications or mutations); a second subtype is defined by PAX5 p.Pro80Arg and biallelic PAX5 alterations."

Integrated genomic analysis defines PAX5alt by heterogeneous PAX5 alteration classes.

⚙

Pathophysiology

7

B-Lineage Developmental Program Disruption

Recurrent B-ALL lesions alter transcriptional regulators of normal hematopoiesis and B-cell development. The exact lesion differs by subtype; this node therefore represents a convergent differentiation defect rather than asserting one universal molecular route across B-ALL.

precursor B cell CL:0000817

KMT2A hgnc:7132 RUNX1 hgnc:10471 PBX1 hgnc:8632 PAX5 hgnc:8619 IKZF1 hgnc:13176

B cell differentiation GO:0030183 ⚠ ABNORMAL

Downstream

Common Lymphoblast Clonal Expansion Developmental lesions cooperate with additional subtype-specific changes to establish a leukemic precursor-B-cell clone.

Show evidence (1 reference)

PMID:23523389 SUPPORT Other

"Many chromosomal rearrangements disrupt genes that regulate normal hematopoiesis and lymphoid development (eg, RUNX1 and ETV6), activate oncogenes (eg, MYC), or constitutively activate tyrosine kinases (eg, ABL1)."

The review directly links recurrent ALL rearrangements to disruption of lymphoid-developmental regulators, while distinguishing this route from oncogene and kinase activation.

Kinase-Activated B-ALL Signaling

BCR::ABL1 in Ph-positive B-ALL and heterogeneous kinase lesions in Ph-like B-ALL activate proliferative signaling. This node is limited to those two kinase-defined contexts and does not generalize kinase dependence to every B-ALL subtype.

ABL1 hgnc:76

RAS protein signal transduction GO:0007265 ↑ INCREASED ERK1 and ERK2 cascade GO:0070371 ↑ INCREASED PI3K-AKT signal transduction GO:0043491 ↑ INCREASED

Downstream

Common Lymphoblast Clonal Expansion Constitutive kinase-pathway output supplies a proliferative and survival route into expansion of the Ph-positive or Ph-like leukemic clone.

Show evidence (2 references)

PMID:28665419 SUPPORT Other

"Similarly, kinase-activating mutations are seen in 90% of the Ph-like ALL. The most common of these include rearrangements involving ABL1, JAK2, PDGFRB, CRLF2 and EPOR, activating mutations of IL7R and FLT3 and deletion of SH2B3, which encodes the JAK2-negative regulator LNK."

The review supports heterogeneous kinase activation in Ph-like ALL; the percentage is retained only inside the exact cohort-review quotation and is not encoded as a universal frequency field.

PMID:41251904 SUPPORT Human Clinical

"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR::ABL1 fusion gene resulting from the translocation t(9;22)."

This supports the defining BCR::ABL1 lesion in the other subtype scoped to this node.

T-ALL NOTCH1 and T-Cell Transcriptional Activation

Activating NOTCH1 lesions and altered T-cell transcription-factor programs are recurrent hallmarks of T-ALL. This node is scoped to T-ALL and does not assert that every case carries an activating NOTCH1 mutation.

NOTCH1 hgnc:7881

Notch signaling pathway GO:0007219 ↑ INCREASED T cell differentiation GO:0030217 ⚠ ABNORMAL

Downstream

Common Lymphoblast Clonal Expansion Activated NOTCH and altered lineage transcription contribute to the proliferative T-lymphoblast state through downstream transcriptional programs.

Show evidence (1 reference)

PMID:28671688 SUPPORT Human Clinical

"Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has not been carried out."

Integrated genomic analysis directly supports NOTCH1 and T-cell transcriptional activation as recurrent T-ALL pathway classes.

T-ALL INK4-ARF Checkpoint Loss

Inactivation of the INK4/ARF tumor-suppressor locus removes cell-cycle and stress-response restraint in a recurrent T-ALL route. It is represented separately from NOTCH activation because the two alterations cooperate but are not interchangeable.

CDKN2A hgnc:1787 CDKN2B hgnc:1788

negative regulation of cell cycle GO:0045786 ↓ DECREASED negative regulation of cyclin-dependent protein kinase activity GO:1904030 ↓ DECREASED

Downstream

Common Lymphoblast Clonal Expansion Reduced checkpoint restraint permits continued cycling of the abnormal T-lineage precursor population.

Show evidence (1 reference)

PMID:28671688 SUPPORT Human Clinical

"Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has not been carried out."

The sequencing study directly identifies INK4/ARF inactivation as a hallmark cooperating pathway in T-ALL.

Common Lymphoblast Clonal Expansion

Biologically distinct B- and T-lineage initiating routes converge on an expanding clone of poorly differentiated lymphoblasts. This is the shared disease-level state, not evidence that all molecular subtypes have the same upstream mechanism.

lymphoblast CL:0017005

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Bone Marrow Failure Accumulating blasts in marrow impair production of normal blood-cell lineages, producing the marrow-failure syndrome.

Extramedullary Leukemic Involvement The leukemic clone can accumulate outside marrow, including lymphoid organs, the CNS, and the mediastinum in T-ALL.

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"The pathogenesis of ALL involves the abnormal proliferation and differentiation of a clonal population of lymphoid cells."

The review directly supports the shared clonal lymphoid-proliferation state while leaving subtype-specific upstream causes separate.

Bone Marrow Failure

Marrow involvement by lymphoblasts reduces effective normal hematopoietic output, producing anemia, thrombocytopenia, and leukopenia and their downstream symptoms.

hemopoiesis GO:0030097 ↓ DECREASED

bone marrow UBERON:0002371

Downstream

Anemia Impaired marrow hematopoiesis lowers red-cell production.

Thrombocytopenia Impaired marrow hematopoiesis lowers platelet production.

Leukopenia Impaired marrow hematopoiesis lowers normal leukocyte production.

Abnormal Bleeding or Bruising Reduced platelet availability contributes to easy bleeding or bruising.

Fatigue Anemia from marrow failure contributes to fatigue.

Recurrent Infections Reduced effective normal leukocyte output increases susceptibility to infection.

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Presentation can be nonspecific, with a combination of constitutional symptoms and signs of bone marrow failure (anemia, thrombocytopenia, leukopenia)."

The review explicitly identifies the three cytopenias as signs of marrow failure in ALL.

Extramedullary Leukemic Involvement

Lymphoblast accumulation outside marrow produces lymph-node, liver, spleen, CNS, or mediastinal findings. The mediastinal presentation is specifically scoped to T-ALL.

Downstream

Lymphadenopathy Leukemic involvement of lymph nodes produces lymphadenopathy.

Hepatosplenomegaly Leukemic involvement of the liver or spleen produces organ enlargement.

Central Nervous System Involvement Leukemic-cell involvement of the CNS produces neurologic or meningeal manifestations.

Mediastinal Mass T-lineage lymphoblast involvement can produce a mediastinal mass.

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Involvement of extramedullary sites commonly occurs and can cause lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients."

The review directly links extramedullary involvement with lymph-node, spleen, and liver findings. The combined numerical estimate remains in the quotation and is not generalized into separate frequency fields.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Blood 4

Anemia HP:0001903

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Presentation can be nonspecific, with a combination of constitutional symptoms and signs of bone marrow failure (anemia, thrombocytopenia, leukopenia)."

The review directly identifies anemia as a marrow-failure sign in ALL.

Thrombocytopenia HP:0001873

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Presentation can be nonspecific, with a combination of constitutional symptoms and signs of bone marrow failure (anemia, thrombocytopenia, leukopenia)."

The review directly identifies thrombocytopenia as a marrow-failure sign in ALL.

Leukopenia Decreased total leukocyte count HP:0001882

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Presentation can be nonspecific, with a combination of constitutional symptoms and signs of bone marrow failure (anemia, thrombocytopenia, leukopenia)."

The review directly identifies leukopenia as a marrow-failure sign in ALL.

Abnormal Bleeding or Bruising HP:0001892

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats), easy bleeding or bruising, fatigue, dyspnea and infection."

The review directly reports easy bleeding or bruising among common ALL symptoms.

Cardiovascular 2

Lymphadenopathy HP:0002716

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Involvement of extramedullary sites commonly occurs and can cause lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients."

The review directly links extramedullary involvement with lymphadenopathy; its combined percentage is not recast as a separate lymphadenopathy frequency.

Hepatosplenomegaly HP:0001433

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Involvement of extramedullary sites commonly occurs and can cause lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients."

The source directly supports liver or spleen enlargement; it is partial support for the combined HPO term.

Immune 1

Recurrent Infections HP:0002719

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats), easy bleeding or bruising, fatigue, dyspnea and infection."

The source reports infection as a common symptom; it is partial support for the more specific recurrent-infections HPO representation.

Constitutional 1

Fatigue HP:0012378

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats), easy bleeding or bruising, fatigue, dyspnea and infection."

The review directly reports fatigue among common ALL symptoms.

Other 2

Central Nervous System Involvement Morphological central nervous system abnormality HP:0002011

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"CNS involvement at time of diagnosis occurs in 5–8% of patients and present most commonly as cranial nerve deficits or meningismus."

The review directly reports CNS involvement, while the available HPO term is broader than leukemia-specific CNS disease and is marked partial.

Mediastinal Mass Anterior mediastinal mass HP:0033827

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"T-cell ALL also may present with a mediastinal mass."

The review directly supports a mediastinal mass as a T-ALL presentation.

🧬

Genetic Associations

8

BCR::ABL1 Fusion (Defining kinase driver of Ph-positive B-ALL)

Gene: ABL1 hgnc:76 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:41251904 SUPPORT Human Clinical

"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by the BCR::ABL1 fusion gene resulting from the translocation t(9;22)."

The source directly identifies the subtype-defining somatic fusion.

KMT2A Rearrangement (Defining rearrangement of KMT2A-rearranged B-ALL)

Gene: KMT2A hgnc:7132 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:39261601 SUPPORT Human Clinical

"Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short median time-to-relapse (12.5-18 months) and poor OS post-relapse (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%)."

The COG cohort treats KMT2A rearrangement as a recurrent subtype-defining lesion and reports its relapse context.

ETV6::RUNX1 Fusion (Defining fusion of ETV6::RUNX1 B-ALL)

Gene: RUNX1 hgnc:10471 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:28418909 SUPPORT Human Clinical

"ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL)."

The review directly supports ETV6::RUNX1 as a recurrent childhood ALL fusion.

TCF3::PBX1 Fusion (Defining fusion of TCF3::PBX1 B-ALL)

Gene: PBX1 hgnc:8632 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:39261601 SUPPORT Human Clinical

"Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short median time-to-relapse (12.5-18 months) and poor OS post-relapse (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%)."

The cohort supports TCF3::PBX1 as a recurrent genetic subtype.

PAX5 Alterations (Defining heterogeneous lesion class of PAX5-altered B-ALL)

Gene: PAX5 hgnc:8619 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:30643249 SUPPORT Human Clinical

"One, PAX5alt (7.4%), has diverse PAX5 alterations (rearrangements, intragenic amplifications or mutations); a second subtype is defined by PAX5 p.Pro80Arg and biallelic PAX5 alterations."

Integrated genomics defines PAX5alt through heterogeneous somatic PAX5 lesions rather than one uniform variant.

NOTCH1 Activating Mutation (Recurrent activating driver in T-ALL)

Gene: NOTCH1 hgnc:7881 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:15472075 SUPPORT Human Clinical

"Here, we report that more than 50% of human T-ALLs, including tumors from all major molecular oncogenic subtypes, have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1."

The human tumor study directly supports recurrent activating somatic NOTCH1 mutations in T-ALL; no frequency field is generalized from it.

IKZF1 Alteration (Cooperating lesion and adverse-risk biomarker in B-ALL)

Gene: IKZF1 hgnc:13176 relationship_type: COOPERATING variant_origin: SOMATIC

Show evidence (1 reference)

PMID:19129520 SUPPORT Human Clinical

"Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL."

The clinical cohort supports IKZF1 alteration as an adverse-risk cooperating biomarker rather than a defining lesion of all B-ALL.

CDKN2A-CDKN2B Loss (Recurrent cooperating checkpoint lesion in T-ALL)

Gene: CDKN2A hgnc:1787 relationship_type: COOPERATING variant_origin: SOMATIC

Show evidence (1 reference)

PMID:28671688 SUPPORT Human Clinical

"Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has not been carried out."

Integrated genomic evidence supports recurrent loss of the locus as a cooperating T-ALL pathway rather than a universal defining lesion.

💊

Medical Actions

10

Risk-Adapted Multi-Agent Chemotherapy

Category: Therapeutic Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Multi-agent induction followed by protocol-defined consolidation, intensification, and maintenance remains a treatment backbone. This entry deliberately avoids presenting one drug list, dose, remission percentage, or pediatric/adult regimen as universal across biologically and clinically heterogeneous ALL.

Mechanism Target:

INHIBITS Common Lymphoblast Clonal Expansion — Cytotoxic combination therapy reduces the leukemic-cell burden and permits recovery of normal hematopoiesis.

Show evidence (1 reference)

PMID:23523389 SUPPORT Human Clinical

"Four to 6 weeks of remission-induction treatment eradicates the initial leukaemic cell burden and restores normal haematopoiesis in 96–99% of children and 78–92% of adults."

The review directly connects induction treatment with reduced leukemic burden and restored hematopoiesis; its era- and population-specific response ranges remain contextual evidence rather than universal fields.

Show evidence (2 references)

PMID:23523389 SUPPORT Other

"The chemotherapy agents typically include a glucocorticoid (prednisone or dexamethasone), vincristine, and asparaginase, with or without anthracycline."

The review supports the multi-agent nature of induction while the entry defers exact composition and intensity to the applicable protocol.

PMID:38306595 SUPPORT Other

"The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and..."

Current adult ELN guidance supports treatment selection that integrates MRD, subgroup biology, difficult clinical contexts, and supportive care.

CNS-Directed Intrathecal Chemotherapy

Category: Therapeutic Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Intrathecal methotrexate-based combination therapy is used to prevent or control CNS leukemia. Cranial irradiation is not represented as a routine default because contemporary protocols often reduce or omit it to limit late toxicity.

Mechanism Target:

INHIBITS Extramedullary Leukemic Involvement — Intrathecal therapy reduces or prevents leukemic burden in the CNS sanctuary compartment.

Show evidence (1 reference)

PMID:23523389 SUPPORT Human Clinical

"Control of CNS disease is a key component of ALL therapy."

The review directly establishes CNS disease control as a core treatment objective.

Show evidence (1 reference)

PMID:23523389 SUPPORT Human Clinical

"protocols replaced cranial irradiation with triple intrathecal chemotherapy (methotrexate, hydrocortisone, and cytarabine) for all newly diagnosed patients"

Protocol evidence supports triple intrathecal chemotherapy as a CNS-directed strategy while avoiding a claim that one schedule is universal.

ABL-Directed Tyrosine Kinase Inhibitor Therapy

Category: Therapeutic Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: ponatinib CHEBI:78543

ABL tyrosine-kinase inhibition is directed at the BCR::ABL1 dependency of Ph-positive B-ALL. Ponatinib retains activity against many kinase-domain resistance variants, but vascular and other toxicities require specialist selection and monitoring. Results from a single-centre phase 2 study of ponatinib plus blinatumomab are encouraging rather than proof that one combination should replace every established regimen.

Mechanism Target:

INHIBITS Kinase-Activated B-ALL Signaling — ABL kinase inhibition suppresses BCR::ABL1-dependent signaling in Ph-positive B-ALL.

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Ponatinib, a third-generation TKI with the ability to inhibit most BCR-ABL1 kinase domain mutations, has recently gained approval for resistant Ph-positive ALL."

The review directly supports ponatinib-mediated inhibition across many BCR::ABL1 kinase-domain variants in resistant Ph-positive ALL.

Show evidence (1 reference)

PMID:36402146 SUPPORT Human Clinical

"The chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response in patients with newly diagnosed and relapsed or refractory Ph-positive acute lymphoblastic leukaemia."

The phase 2 trial supports activity of the combination in its studied population; the entry explicitly retains the single-centre, single-arm limitation.

Blinatumomab CD19-CD3 Bispecific Therapy

Category: Therapeutic Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: blinatumomab NCIT:C62528

Blinatumomab brings CD3-positive T cells into proximity with CD19-positive B-lineage blasts. Its established contexts include relapsed/refractory and MRD-directed use; E1910 additionally supports incorporation into consolidation for adults in MRD-negative remission from B-cell precursor ALL.

Mechanism Target:

INHIBITS Common Lymphoblast Clonal Expansion — CD19-CD3 engagement creates cytolytic synapses that kill CD19-positive B-lineage blasts.

Show evidence (1 reference)

PMID:39047240 SUPPORT Human Clinical

"Blinatumomab is a bispecific T-cell engager molecule composed of an anti-CD19 variable region linked to an anti-CD3 variable region that brings T cells in proximity to leukemic blasts to form cytolytic synapses, leading to apoptosis and lysis of the blasts."

The trial report directly states the CD19-CD3 cytolytic mechanism.

Show evidence (1 reference)

PMID:39047240 SUPPORT Human Clinical

"The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival."

Randomized E1910 evidence supports consolidation blinatumomab in the explicitly stated adult MRD-negative remission population.

Inotuzumab Ozogamicin CD22-Directed Therapy

Category: Therapeutic Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: inotuzumab ozogamicin NCIT:C71542

Inotuzumab ozogamicin binds CD22 and delivers calicheamicin intracellularly, causing DNA double-strand breaks and apoptosis. Its relapsed/refractory benefit must be balanced against serious toxicities, including hepatic veno-occlusive disease reported in trials.

Mechanism Target:

INHIBITS Common Lymphoblast Clonal Expansion — CD22-mediated internalization delivers calicheamicin to B-lineage blasts and induces apoptotic DNA damage.

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Inotuzumab ozogamicin (InO) is a monoclonal antibody against CD22 that is conjugated to calicheamicin, a potent cytotoxic compound that induces double-strand DNA breaks."

The review directly supports CD22 targeting and the conjugated cytotoxic mechanism.

Show evidence (1 reference)

PMID:27292104 SUPPORT Human Clinical

"The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the standard-therapy group"

Randomized phase 3 evidence supports superior remission rates in adults with relapsed or refractory ALL; the population and endpoint remain explicit.

Tisagenlecleucel CD19 CAR-T Cell Therapy

Category: Therapeutic Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: tisagenlecleucel NCIT:C102758

Autologous T cells engineered with a CD19-directed chimeric antigen receptor can expand and persist after infusion and produce durable remissions in relapsed or refractory B-cell ALL. Cytokine-release syndrome, neurologic toxicity, B-cell aplasia, manufacturing feasibility, and eligibility require specialist management.

Mechanism Target:

INHIBITS Common Lymphoblast Clonal Expansion — CD19-directed CAR T cells recognize and eliminate CD19-positive B-lineage blasts.

Show evidence (1 reference)

PMID:29385370 SUPPORT Human Clinical

"In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects."

The global multicentre study supports durable remission and cellular persistence in the explicitly scoped pediatric and young-adult population.

Show evidence (1 reference)

PMID:29385370 SUPPORT Human Clinical

"In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects."

This supports tisagenlecleucel efficacy and also preserves the reported high-grade-toxicity qualification.

Investigational Allogeneic CD19 CAR-T Cell Therapy (Phase 1)

Category: Therapeutic Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262

A non-gene-edited allogeneic CD19 CAR-T product showed early antileukemic activity without observed graft-versus-host disease in a very small phase 1 study. The cohort size, single-arm design, toxicities, and limited survival estimates preclude treating this approach as established or equivalent to authorized autologous CAR-T therapy.

Mechanism Target:

INHIBITS Common Lymphoblast Clonal Expansion — Donor-derived CD19-directed CAR T cells are intended to eliminate CD19-positive B-lineage blasts.

Show evidence (1 reference)

PMID:42237011 SUPPORT Human Clinical

"At day 28, 8 of 9 evaluable patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi)."

The small phase 1 cohort provides early clinical activity consistent with blast elimination but does not establish comparative efficacy.

Show evidence (2 references)

PMID:42237011 SUPPORT Human Clinical

"No GVHD was observed."

Absence of observed GVHD in this tiny cohort is a safety observation, not proof that the platform eliminates GVHD risk.

PMID:42237011 SUPPORT Human Clinical

"At day 28, 8 of 9 evaluable patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi)."

The response result is explicitly contextualized as nine evaluable patients in an open-label, single-arm phase 1 study.

Nelarabine-Containing Therapy for T-ALL

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Nelarabine is converted to a purine nucleoside analogue that preferentially accumulates in T cells, incorporates into DNA, inhibits DNA synthesis, and induces apoptosis. Randomized AALL0434 evidence supports its addition to an augmented BFM backbone in children and young adults with newly diagnosed T-ALL.

Mechanism Target:

INHIBITS Common Lymphoblast Clonal Expansion — DNA incorporation inhibits synthesis and induces apoptosis in T-lineage lymphoblasts.

Show evidence (1 reference)

PMID:28665419 SUPPORT Other

"Nelarabine accumulates in T cells at a high rate and incorporates into DNA causing an inhibition of DNA synthesis and subsequent apoptosis."

The review directly states the T-cell-selective cytotoxic mechanism.

Show evidence (1 reference)

PMID:32813610 SUPPORT Human Clinical

"The addition of nelarabine to ABFM therapy improved DFS for children and young adults with newly diagnosed T-ALL without increased toxicity."

Randomized phase 3 evidence supports addition of nelarabine in the specified pediatric and young-adult frontline context.

Allogeneic Hematopoietic Stem Cell Transplantation

Category: Therapeutic Action: hematopoietic stem cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Allogeneic transplantation is reserved for selected patients rather than applied uniformly across ALL. The balance among relapse risk, transplant morbidity and mortality, modern immunotherapies, and MRD response requires protocol- and patient-specific assessment.

Show evidence (2 references)

PMID:28665419 SUPPORT Other

"Despite advances in management, the backbone of therapy remains multi-agent chemotherapy with vincristine, corticosteroids and an anthracycline with allogeneic stem cell transplantation for eligible candidates."

The review supports transplantation for eligible patients, while current selection has evolved and is therefore represented cautiously as partial support.

PMID:38306595 SUPPORT Other

"It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care."

Current ELN guidance supports integrating MRD, newer immunotherapy, and subgroup context into adult treatment decisions; the abstract does not state a universal transplant indication.

Supportive and Toxicity-Directed Care

Category: Therapeutic Action: supportive care Ontology label: Supportive Care NCIT:C15747

ALL treatment requires preventive and responsive supportive care across induction, consolidation, immunotherapy, transplantation, and follow-up. Exact interventions depend on current counts, organ function, regimen, toxicities, infection risk, and local standards.

Show evidence (1 reference)

PMID:38306595 SUPPORT Other

"The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and..."

Current adult ELN recommendations explicitly include supportive care and late effects within comprehensive ALL management.

🔬

Biochemical Markers

1

Measurable Residual Disease (VARIABLE)

Pathograph Readouts

Readout Of Common Lymphoblast Clonal Expansion Positive Monitoring

Detectable MRD after therapy reports persistence of the leukemic clone; lower or undetectable signal reports deeper response within the limits of the assay used.

Show evidence (1 reference)

PMID:18388178 SUPPORT Human Clinical

"The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL)."

The study directly supports flow-cytometric MRD as a timed post-treatment measurement of residual B-ALL burden.

Predicts Common Lymphoblast Clonal Expansion Positive Prognostic

Detectable end-induction marrow MRD predicts worse event-free survival; this is a prognostic association and does not itself prove that MRD causes relapse.

Show evidence (1 reference)

PMID:18388178 SUPPORT Human Clinical

"Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis."

The COG analysis directly supports day-29 marrow MRD as a prognostic predictor while the schema relationship remains noncausal.

Show evidence (2 references)

PMID:18388178 SUPPORT Human Clinical

"The presence of MRD in day-8 blood and day-29 marrow MRD was associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.01% to 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients (59% +/- 5% vs 88% +/- 1% 5-year EFS)."

This large pediatric B-ALL cohort establishes the time-dependent prognostic significance of flow-cytometric MRD.

PMID:29284596 SUPPORT Human Clinical

"The higher analytic sensitivity and lower false-negative rate of HTS improves upon FC for MRD detection in pediatric B-ALL by identifying a novel subset of patients at end of induction who are essentially cured using current chemotherapy and identifying MRD at 0.01% in up to one-third of..."

The paired-sample study supports greater analytic sensitivity of high-throughput sequencing than flow cytometry in pediatric B-ALL without implying that the result applies unchanged to every ALL population.

🔬

Diagnosis

3

Morphologic Blast Assessment and Flow-Cytometric Lineage Assignment

Initial diagnosis combines microscopic recognition of lymphoblasts with flow-cytometric immunophenotyping to assign B- or T-lineage and maturational stage. Neither morphology nor a single marker should be treated as a molecular subtype assignment.

flow cytometry procedure NCIT:C16585

Results: A lymphoblast population with a coherent precursor B- or T-lineage immunophenotype supports ALL in the appropriate marrow or blood context.

Show evidence (2 references)

PMID:23523389 SUPPORT Other

"Morphological identification of lymphoblasts by microscopy and immunophenotypic determination of lineage commitment and developmental stage by flow cytometry are essential for correct diagnosis of ALL."

The review directly supports the paired morphology and flow-cytometry workflow for lineage-aware initial diagnosis.

PMID:28665419 SUPPORT Other

"Diagnosis is established by the presence of 20% or more lymphoblasts in the bone marrow or peripheral blood."

The review provides its stated blast threshold for a leukemic presentation; current entity-defining classification still requires integrated lineage and genomic interpretation.

Cytogenetic and Molecular Subtype Assignment

Karyotype, cellular DNA-content assessment, FISH, fusion testing, and copy-number or sequencing assays identify subtype-defining rearrangements, aneuploidy, and cryptic lesions. The selected assay set must cover both established and newly recognized B- and T-ALL entities.

diagnostic procedure NCIT:C18020

Results: A defining fusion, ploidy state, rearrangement, or molecular profile assigns the corresponding subtype and informs risk and targeted-treatment choices.

Show evidence (2 references)

PMID:23523389 SUPPORT Other

"Chromosomal analysis still plays an important role in the initial cytogenetic work-up. RT-PCR, FISH/multiplex ligation-dependent probe amplification, and flow cytometry are used to identify leukaemia-specific translocations, submicroscopic chromosomal abnormalities, and cellular DNA content,..."

The review directly supports complementary cytogenetic and molecular approaches to defining ALL lesions.

PMID:38295337 SUPPORT Other

"The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors, and risk stratification as well as definitions of endpoints..."

Current ELN consensus supports integrated diagnosis, biologic characterization, and risk stratification in adults.

Post-Treatment MRD Response Assessment

Flow cytometry or clonotype-based high-throughput sequencing measures residual disease at protocol-defined response milestones. This is a monitoring and prognostic assessment after the initial diagnosis, not a replacement for lineage or subtype classification.

diagnostic procedure NCIT:C18020

Results: Detectable residual leukemic cells or clonotypes quantify response depth and contribute to risk-adapted management, with assay-specific sensitivity and thresholds reported explicitly.

Show evidence (2 references)

PMID:18388178 SUPPORT Human Clinical

"The presence of MRD in day-8 blood and day-29 marrow MRD was associated with shorter event-free survival (EFS) in all risk groups"

Timed flow-cytometric MRD measurements carry prognostic information after therapy in pediatric precursor B-ALL.

PMID:29284596 SUPPORT Human Clinical

"The higher analytic sensitivity and lower false-negative rate of HTS improves upon FC for MRD detection in pediatric B-ALL"

The paired-sample study supports high-throughput sequencing as a more analytically sensitive MRD method in its pediatric B-ALL context.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Acute Lymphoblastic Leukemia:

Acute Myeloid Leukemia MONDO:0018874

Overlapping Features AML can also present with an acute marrow blast process and cytopenias, so lineage must be assigned rather than inferred from morphology alone.

Distinguishing Features

A coherent myeloid rather than precursor B- or T-lineage immunophenotype supports AML.
Integrated cytogenetic and molecular findings can identify an AML-defining entity.

Show evidence (1 reference)

PMID:23523389 SUPPORT Other

"Morphological identification of lymphoblasts by microscopy and immunophenotypic determination of lineage commitment and developmental stage by flow cytometry are essential for correct diagnosis of ALL."

The source establishes lineage immunophenotyping as essential for ALL; its use here to distinguish an acute myeloid process is conservative and therefore marked partial.

Mixed-Phenotype Acute Leukemia

Overlapping Features Mixed-phenotype acute leukemia enters the differential when the blast population meets lineage-defining criteria for more than one lineage or distinct blast populations establish different lineages.

Distinguishing Features

Apply lineage-defining immunophenotypic criteria rather than labeling ambiguous marker expression as ALL.
Integrate recurrent fusion and cytogenetic results because they may alter entity assignment.

Show evidence (1 reference)

PMID:23523389 SUPPORT Other

"Morphological identification of lymphoblasts by microscopy and immunophenotypic determination of lineage commitment and developmental stage by flow cytometry are essential for correct diagnosis of ALL."

The source supports explicit lineage assignment but does not enumerate mixed-phenotype criteria, so support is partial.

Lymphoblastic Lymphoma

Overlapping Features Lymphoblastic lymphoma and ALL form a biologic spectrum. A tissue-predominant mass with limited marrow or blood disease favors the lymphoma designation, while a leukemic marrow or blood presentation favors ALL; classification should follow the applicable contemporary framework.

Distinguishing Features

Establish the anatomic distribution and marrow or blood blast burden rather than relying on lineage alone.
Retain B- versus T-lineage and genomic subtype information across the leukemia-lymphoma spectrum.

Show evidence (1 reference)

PMID:36422706 SUPPORT Other

"The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes both revisions to subtypes previously outlined in the 2016 WHO classification and several newly described entities."

The ICC supports shared lineage and genomic taxonomy across ALL/lymphoblastic lymphoma, while the excerpt does not provide a numeric marrow boundary and is marked partial.

📊

Related Datasets

5

Genetic landscape of pediatric Infant Acute Lymphoblastic leukemia ega:EGAS00001000246

We performed whole genome sequencing of tumor and normal DNA samples obtained from 22 infant ALL cases with MLL rearrangements. In addition, we sequenced 2 paired diagnostic-relapse samples. Using complementary pipelines, somatically acquired genetic changes were analyzed, including single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes. In addition, exome sequencing was performed on paired diagnostic and normal DNA samples obtained from 20 cases of non-infant MLL rearranged leukemias and somatic mutations in the coding regions were identified.

human WGS

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Acute Lymphoblastic Leukemia"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Whole genome sequencing of pediatric BCR-ABL1 positive acute lymphoblastic leukemia ega:EGAS00001000253

We performed whole-genome sequencing of 18 paired tumor/normal BCR-ABL1+ leukemia genomes and analyzed single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the tumor and normal genomes

human WGS

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Acute Lymphoblastic Leukemia"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Exome sequencing identifies mutation of the ribosome in T-cell acute lymphoblastic leukemia ega:EGAS00001000296

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and responds well to therapy in children, but not in adults. We used exome sequencing of 67 T-cell ALL (T- ALL) samples to gain insight in the mutational spectrum and age related differences of these leukemias. We detected protein-altering mutations in 508 genes, with an average of 8.2 mutations in pediatric and 21.0 in adult T-ALL. Based on stringent filtering, we predict 15 of these genes to be drivers, including 7 genes that were not previously implicated in T-ALL.

human WES

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Acute Lymphoblastic Leukemia"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Metabolomics of B-cell Acute Lymphoblastic Leukemia in Response to Adipocyte Conditioned Media metabolomics_workbench:ST002383

Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Acute Lymphoblastic Leukemia"). Retrieved 2026-08-02.

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia massive:MSV000084862

Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Acute Lymphoblastic Leukemia"). Retrieved 2026-08-02.

{ }

Source YAML

click to show

name: Acute Lymphoblastic Leukemia
creation_date: '2026-05-08T12:00:00Z'
description: >-
  Acute lymphoblastic leukemia (ALL) is a precursor lymphoid malignancy in
  which an abnormal clone of B- or T-lineage lymphoblasts expands in bone
  marrow, blood, and sometimes extramedullary sites. Modern classification
  integrates lineage, ploidy, recurrent rearrangements, sequence variants,
  and expression-defined entities. These biologically distinct routes
  converge on impaired lymphoid differentiation, abnormal survival or
  proliferation, and accumulation of blasts that disrupt normal hematopoiesis.
categories:
- Hematologic Malignancy
- Acute Leukemia
parents:
- leukemia
disease_term:
  preferred_term: acute lymphoblastic leukemia
  term:
    id: MONDO:0004967
    label: acute lymphoblastic leukemia
has_subtypes:
- name: B-ALL
  display_name: B-cell acute lymphoblastic leukemia
  classification: lineage
  children:
  - Ph-positive
  - Ph-like
  - KMT2A-rearranged
  - ETV6-RUNX1
  - TCF3-PBX1
  - High hyperdiploidy
  - Hypodiploidy
  - iAMP21
  - PAX5-altered
  description: >-
    Precursor B-lineage ALL. Current WHO and ICC frameworks further classify
    most cases by ploidy, recurrent rearrangement, sequence alteration, or
    expression-defined genetic subtype.
  evidence:
  - reference: PMID:36422706
    reference_title: International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The updated International Consensus Classification (ICC) of B-acute
      lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL)
      includes both revisions to subtypes previously outlined in the 2016 WHO
      classification and several newly described entities.
    explanation: >-
      The ICC establishes B-ALL and T-ALL as lineage families with revised and
      newly defined subtypes.
- name: T-ALL
  display_name: T-cell acute lymphoblastic leukemia
  classification: lineage
  children:
  - ETP-ALL
  description: >-
    Precursor T-lineage ALL characterized by recurrent disruption of T-cell
    transcriptional programs, NOTCH1 signaling, cell-cycle control, and other
    stage-associated pathways.
  evidence:
  - reference: PMID:28671688
    reference_title: The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic alterations that activate NOTCH1 signaling and T cell transcription
      factors, coupled with inactivation of the INK4/ARF tumor suppressors, are
      hallmarks of T-lineage acute lymphoblastic leukemia (T-ALL), but detailed
      genome-wide sequencing of large T-ALL cohorts has not been carried out.
    explanation: >-
      Integrated sequencing defines the major recurrent pathway classes in
      human T-ALL.
- name: ETP-ALL
  display_name: Early T-cell precursor acute lymphoblastic leukemia
  classification: T-lineage developmental subtype
  description: >-
    An early T-precursor subtype with a distinct immunophenotypic and genomic
    profile, including enrichment for lesions also seen in stem or myeloid
    programs. It is classified within the T-ALL family rather than treated as
    a B-lineage genetic subtype.
  evidence:
  - reference: PMID:36422706
    reference_title: International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      T-ALL classification is also updated to incorporate BCL11B-activating
      rearrangements into early T-precursor (ETP) ALL taxonomy.
    explanation: >-
      The ICC explicitly places early T-precursor ALL in the updated T-ALL
      taxonomy.
- name: Ph-positive
  display_name: BCR::ABL1-positive / Philadelphia chromosome-positive B-ALL
  classification: recurrent fusion
  description: >-
    B-ALL with t(9;22) and BCR::ABL1. The constitutively active ABL1 kinase
    creates a targetable signaling dependency and makes this subtype distinct
    from expression-similar BCR::ABL1-like disease.
  subtype_term:
    preferred_term: B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
    term:
      id: MONDO:0035940
      label: B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
  evidence:
  - reference: PMID:41251904
    reference_title: "Philadelphia chromosome-positive acute lymphoblastic leukemia: exploring microRNA-based strategies to improve outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
      is characterized by the BCR::ABL1 fusion gene resulting from the
      translocation t(9;22).
    explanation: >-
      This defines the BCR::ABL1 fusion lesion of Ph-positive ALL.
- name: Ph-like
  display_name: BCR::ABL1-like / Philadelphia chromosome-like B-ALL
  classification: kinase-activated expression subtype
  description: >-
    B-ALL with a BCR::ABL1-like expression profile but no BCR::ABL1 fusion.
    Diverse ABL-class, JAK-STAT, cytokine-receptor, and other kinase lesions
    require molecular characterization rather than inference from the label.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Ten to 12 percent of B-ALL cases exhibit a gene expression profile similar
      to that of BCR-ABL1 ALL but are BCR-ABL1-negative, commonly show IKZF1
      alteration, and have a poor outcome
    explanation: >-
      The review directly defines the BCR::ABL1-like expression subtype and
      separates it from BCR::ABL1-positive disease.
- name: KMT2A-rearranged
  display_name: KMT2A-rearranged B-ALL
  classification: recurrent rearrangement
  description: >-
    B-ALL with a KMT2A rearrangement and one of several fusion partners. It is
    prominent in infant ALL and has clinically important relapse behavior.
  subtype_term:
    preferred_term: B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
    term:
      id: MONDO:0035941
      label: B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
  evidence:
  - reference: PMID:39261601
    reference_title: "Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short
      median time-to-relapse (12.5-18 months) and poor OS post-relapse
      (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%).
    explanation: >-
      The COG cohort identifies KMT2A rearrangement as a clinically distinct
      recurrent subtype.
- name: ETV6-RUNX1
  display_name: ETV6::RUNX1 B-ALL
  classification: recurrent fusion
  description: >-
    B-ALL with t(12;21) and ETV6::RUNX1, a childhood-enriched recurrent fusion
    with a distinctive relapse pattern.
  subtype_term:
    preferred_term: B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)
    term:
      id: MONDO:0035942
      label: B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)
  evidence:
  - reference: PMID:28418909
    reference_title: Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute
      lymphoblastic leukemia (ALL).
    explanation: >-
      This supports ETV6::RUNX1 as a recurrent childhood ALL fusion subtype.
- name: TCF3-PBX1
  display_name: TCF3::PBX1 B-ALL
  classification: recurrent fusion
  description: >-
    B-ALL with t(1;19) and TCF3::PBX1. Its molecular identity is retained even
    though outcomes depend on treatment context.
  evidence:
  - reference: PMID:39261601
    reference_title: "Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short
      median time-to-relapse (12.5-18 months) and poor OS post-relapse
      (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%).
    explanation: >-
      The cohort treats TCF3::PBX1 as a recurrent genetic subtype.
- name: High hyperdiploidy
  display_name: High-hyperdiploid B-ALL
  classification: aneuploid subtype
  description: >-
    B-ALL defined by high hyperdiploidy and recurrent whole-chromosome gains.
  subtype_term:
    preferred_term: B-lymphoblastic leukemia/lymphoma with hyperdiploidy
    term:
      id: MONDO:0035943
      label: B-lymphoblastic leukemia/lymphoma with hyperdiploidy
  evidence:
  - reference: PMID:35732829
    reference_title: "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
    explanation: >-
      WHO-HAEM5 lists high-hyperdiploid B-lymphoblastic leukemia/lymphoma as a
      classified entity.
- name: Hypodiploidy
  display_name: Hypodiploid B-ALL
  classification: aneuploid subtype
  description: >-
    B-ALL with a hypodiploid chromosome complement, encompassing biologically
    distinct near-haploid and low-hypodiploid groups.
  subtype_term:
    preferred_term: B-lymphoblastic leukemia/lymphoma with hypodiploidy
    term:
      id: MONDO:0035944
      label: B-lymphoblastic leukemia/lymphoma with hypodiploidy
  evidence:
  - reference: PMID:36422706
    reference_title: International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      B-ALL classification is modified to further subclassify
      BCR::ABL1-positive B-ALL and hypodiploid B-ALL.
    explanation: >-
      The ICC explicitly recognizes and further subdivides hypodiploid B-ALL.
- name: iAMP21
  display_name: B-ALL with intrachromosomal amplification of chromosome 21
  classification: focal amplification subtype
  description: >-
    B-ALL with intrachromosomal amplification of chromosome 21. Accurate
    genomic detection matters because unusual amplification patterns may not
    satisfy a simple FISH rule.
  evidence:
  - reference: PMID:35771717
    reference_title: Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acute lymphoblastic leukemia (B-ALL) with intrachromosomal amplification
      of chromosome 21 (iAMP21-ALL) represents a recurrent high-risk cytogenetic
      abnormality and accurate identification is critical for appropriate
      clinical management.
    explanation: >-
      This cohort supports iAMP21 as a recurrent cytogenetic B-ALL subtype.
- name: PAX5-altered
  display_name: PAX5-altered / PAX5alt B-ALL
  classification: transcription-factor altered subtype
  description: >-
    A B-ALL expression subtype enriched for diverse PAX5 rearrangements,
    mutations, and focal or intragenic amplifications rather than one uniform
    rearrangement.
  evidence:
  - reference: PMID:30643249
    reference_title: PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One, PAX5alt (7.4%), has diverse PAX5 alterations (rearrangements,
      intragenic amplifications or mutations); a second subtype is defined by
      PAX5 p.Pro80Arg and biallelic PAX5 alterations.
    explanation: >-
      Integrated genomic analysis defines PAX5alt by heterogeneous PAX5
      alteration classes.

pathophysiology:
- name: B-Lineage Developmental Program Disruption
  description: >-
    Recurrent B-ALL lesions alter transcriptional regulators of normal
    hematopoiesis and B-cell development. The exact lesion differs by subtype;
    this node therefore represents a convergent differentiation defect rather
    than asserting one universal molecular route across B-ALL.
  subtypes:
  - B-ALL
  - KMT2A-rearranged
  - ETV6-RUNX1
  - TCF3-PBX1
  - PAX5-altered
  genes:
  - preferred_term: KMT2A
    term:
      id: hgnc:7132
      label: KMT2A
  - preferred_term: RUNX1
    term:
      id: hgnc:10471
      label: RUNX1
  - preferred_term: PBX1
    term:
      id: hgnc:8632
      label: PBX1
  - preferred_term: PAX5
    term:
      id: hgnc:8619
      label: PAX5
  - preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  cell_types:
  - preferred_term: precursor B cell
    term:
      id: CL:0000817
      label: precursor B cell
  biological_processes:
  - preferred_term: B cell differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030183
      label: B cell differentiation
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Many chromosomal rearrangements disrupt genes that regulate normal
      hematopoiesis and lymphoid development (eg, RUNX1 and ETV6), activate
      oncogenes (eg, MYC), or constitutively activate tyrosine kinases (eg,
      ABL1).
    explanation: >-
      The review directly links recurrent ALL rearrangements to disruption of
      lymphoid-developmental regulators, while distinguishing this route from
      oncogene and kinase activation.
  downstream:
  - target: Common Lymphoblast Clonal Expansion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired precursor B-cell differentiation
    - cooperation with subtype-specific structural and sequence alterations
    description: >-
      Developmental lesions cooperate with additional subtype-specific changes
      to establish a leukemic precursor-B-cell clone.
    evidence:
    - reference: PMID:23523389
      reference_title: Acute lymphoblastic leukaemia.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Importantly, many ALL subtypes are characterized by distinct
        constellations of structural genetic alterations that together drive
        establishment of the leukaemic clone.
      explanation: >-
        The review explicitly states that subtype-specific constellations of
        lesions jointly establish the leukemic clone; the edge is indirect
        because no single universal intermediate sequence is established.
- name: Kinase-Activated B-ALL Signaling
  description: >-
    BCR::ABL1 in Ph-positive B-ALL and heterogeneous kinase lesions in Ph-like
    B-ALL activate proliferative signaling. This node is limited to those two
    kinase-defined contexts and does not generalize kinase dependence to every
    B-ALL subtype.
  subtypes:
  - Ph-positive
  - Ph-like
  genes:
  - preferred_term: ABL1
    term:
      id: hgnc:76
      label: ABL1
  conforms_to: "sustaining_proliferative_signaling#Constitutive Mitogenic Pathway Activation"
  biological_processes:
  - preferred_term: RAS protein signal transduction
    modifier: INCREASED
    term:
      id: GO:0007265
      label: Ras protein signal transduction
  - preferred_term: ERK1 and ERK2 cascade
    modifier: INCREASED
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  - preferred_term: PI3K-AKT signal transduction
    modifier: INCREASED
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Similarly, kinase-activating mutations are seen in 90% of the Ph-like
      ALL. The most common of these include rearrangements involving ABL1,
      JAK2, PDGFRB, CRLF2 and EPOR, activating mutations of IL7R and FLT3 and
      deletion of SH2B3, which encodes the JAK2-negative regulator LNK.
    explanation: >-
      The review supports heterogeneous kinase activation in Ph-like ALL; the
      percentage is retained only inside the exact cohort-review quotation and
      is not encoded as a universal frequency field.
  - reference: PMID:41251904
    reference_title: "Philadelphia chromosome-positive acute lymphoblastic leukemia: exploring microRNA-based strategies to improve outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
      is characterized by the BCR::ABL1 fusion gene resulting from the
      translocation t(9;22).
    explanation: >-
      This supports the defining BCR::ABL1 lesion in the other subtype scoped
      to this node.
  downstream:
  - target: Common Lymphoblast Clonal Expansion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - constitutive kinase signaling
    - RAS-MAPK and PI3K-AKT pathway output
    description: >-
      Constitutive kinase-pathway output supplies a proliferative and survival
      route into expansion of the Ph-positive or Ph-like leukemic clone.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The pathogenesis of ALL involves the abnormal proliferation and
        differentiation of a clonal population of lymphoid cells.
      explanation: >-
        The review supports clonal lymphoid proliferation as the disease-level
        endpoint. The link from heterogeneous kinase output is marked partial
        and indirect because it is subtype-specific and traverses multiple
        signaling intermediates.
- name: T-ALL NOTCH1 and T-Cell Transcriptional Activation
  description: >-
    Activating NOTCH1 lesions and altered T-cell transcription-factor programs
    are recurrent hallmarks of T-ALL. This node is scoped to T-ALL and does not
    assert that every case carries an activating NOTCH1 mutation.
  subtypes:
  - T-ALL
  genes:
  - preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  biological_processes:
  - preferred_term: Notch signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007219
      label: Notch signaling pathway
  - preferred_term: T cell differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030217
      label: T cell differentiation
  evidence:
  - reference: PMID:28671688
    reference_title: The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic alterations that activate NOTCH1 signaling and T cell
      transcription factors, coupled with inactivation of the INK4/ARF tumor
      suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia
      (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has
      not been carried out.
    explanation: >-
      Integrated genomic analysis directly supports NOTCH1 and T-cell
      transcriptional activation as recurrent T-ALL pathway classes.
  downstream:
  - target: Common Lymphoblast Clonal Expansion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered T-cell developmental transcription
    - NOTCH-dependent growth and survival programs
    description: >-
      Activated NOTCH and altered lineage transcription contribute to the
      proliferative T-lymphoblast state through downstream transcriptional
      programs.
    evidence:
    - reference: PMID:15472075
      reference_title: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These findings greatly expand the role of activated NOTCH1 in the
        molecular pathogenesis of human T-ALL and provide a strong rationale
        for targeted therapies that interfere with NOTCH signaling.
      explanation: >-
        Human T-ALL mutation data support activated NOTCH1 in pathogenesis; the
        edge is indirect because the quoted evidence does not enumerate every
        intervening transcriptional effector.
- name: T-ALL INK4-ARF Checkpoint Loss
  description: >-
    Inactivation of the INK4/ARF tumor-suppressor locus removes cell-cycle and
    stress-response restraint in a recurrent T-ALL route. It is represented
    separately from NOTCH activation because the two alterations cooperate but
    are not interchangeable.
  subtypes:
  - T-ALL
  genes:
  - preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  - preferred_term: CDKN2B
    term:
      id: hgnc:1788
      label: CDKN2B
  conforms_to: "evading_growth_suppressors#Loss of Cell-Cycle Checkpoint Control"
  biological_processes:
  - preferred_term: negative regulation of cell cycle
    modifier: DECREASED
    term:
      id: GO:0045786
      label: negative regulation of cell cycle
  - preferred_term: negative regulation of cyclin-dependent protein kinase activity
    modifier: DECREASED
    term:
      id: GO:1904030
      label: negative regulation of cyclin-dependent protein kinase activity
  evidence:
  - reference: PMID:28671688
    reference_title: The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic alterations that activate NOTCH1 signaling and T cell
      transcription factors, coupled with inactivation of the INK4/ARF tumor
      suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia
      (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has
      not been carried out.
    explanation: >-
      The sequencing study directly identifies INK4/ARF inactivation as a
      hallmark cooperating pathway in T-ALL.
  downstream:
  - target: Common Lymphoblast Clonal Expansion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - loss of cyclin-dependent kinase inhibition
    - relaxed G1-S checkpoint control
    description: >-
      Reduced checkpoint restraint permits continued cycling of the abnormal
      T-lineage precursor population.
    evidence:
    - reference: PMID:28671688
      reference_title: The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Genetic alterations that activate NOTCH1 signaling and T cell
        transcription factors, coupled with inactivation of the INK4/ARF tumor
        suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia
        (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has
        not been carried out.
      explanation: >-
        The human genomic association supports checkpoint loss as a cooperating
        T-ALL mechanism, while the specific intermediates to clonal expansion
        remain an inferred canonical cell-cycle route and are marked partial.
- name: Common Lymphoblast Clonal Expansion
  description: >-
    Biologically distinct B- and T-lineage initiating routes converge on an
    expanding clone of poorly differentiated lymphoblasts. This is the shared
    disease-level state, not evidence that all molecular subtypes have the same
    upstream mechanism.
  subtypes:
  - B-ALL
  - T-ALL
  cell_types:
  - preferred_term: lymphoblast
    term:
      id: CL:0017005
      label: lymphoblast
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The pathogenesis of ALL involves the abnormal proliferation and
      differentiation of a clonal population of lymphoid cells.
    explanation: >-
      The review directly supports the shared clonal lymphoid-proliferation
      state while leaving subtype-specific upstream causes separate.
  downstream:
  - target: Bone Marrow Failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - marrow accumulation of malignant lymphoblasts
    - suppression or displacement of normal hematopoietic output
    description: >-
      Accumulating blasts in marrow impair production of normal blood-cell
      lineages, producing the marrow-failure syndrome.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Most of the clinical manifestations of ALL reflect the accumulation of
        malignant, poorly differentiated lymphoid cells within the bone marrow,
        peripheral blood, and, extramedullary sites. Presentation can be
        nonspecific, with a combination of constitutional symptoms and signs of
        bone marrow failure (anemia, thrombocytopenia, leukopenia).
      explanation: >-
        The review directly attributes marrow-failure manifestations to
        accumulation of malignant poorly differentiated lymphoid cells.
  - target: Extramedullary Leukemic Involvement
    causal_link_type: DIRECT
    description: >-
      The leukemic clone can accumulate outside marrow, including lymphoid
      organs, the CNS, and the mediastinum in T-ALL.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Most of the clinical manifestations of ALL reflect the accumulation of
        malignant, poorly differentiated lymphoid cells within the bone marrow,
        peripheral blood, and, extramedullary sites.
      explanation: >-
        The review directly describes malignant lymphoid-cell accumulation at
        extramedullary sites.
- name: Bone Marrow Failure
  description: >-
    Marrow involvement by lymphoblasts reduces effective normal hematopoietic
    output, producing anemia, thrombocytopenia, and leukopenia and their
    downstream symptoms.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  biological_processes:
  - preferred_term: hemopoiesis
    modifier: DECREASED
    term:
      id: GO:0030097
      label: hemopoiesis
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Presentation can be nonspecific, with a combination of constitutional
      symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
      leukopenia).
    explanation: >-
      The review explicitly identifies the three cytopenias as signs of marrow
      failure in ALL.
  downstream:
  - target: Anemia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced erythroid output
    description: Impaired marrow hematopoiesis lowers red-cell production.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Presentation can be nonspecific, with a combination of constitutional
        symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
        leukopenia).
      explanation: The review explicitly lists anemia as a sign of ALL marrow failure.
  - target: Thrombocytopenia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced megakaryocytic and platelet output
    description: Impaired marrow hematopoiesis lowers platelet production.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Presentation can be nonspecific, with a combination of constitutional
        symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
        leukopenia).
      explanation: The review explicitly lists thrombocytopenia as a sign of ALL marrow failure.
  - target: Leukopenia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced normal leukocyte output
    description: Impaired marrow hematopoiesis lowers normal leukocyte production.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Presentation can be nonspecific, with a combination of constitutional
        symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
        leukopenia).
      explanation: The review explicitly lists leukopenia as a sign of ALL marrow failure.
  - target: Abnormal Bleeding or Bruising
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - thrombocytopenia
    - impaired primary hemostasis
    description: Reduced platelet availability contributes to easy bleeding or bruising.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats),
        easy bleeding or bruising, fatigue, dyspnea and infection.
      explanation: >-
        The review reports easy bleeding or bruising among common ALL symptoms;
        thrombocytopenia is the stated intermediate from marrow failure.
  - target: Fatigue
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - anemia
    - reduced oxygen delivery
    description: Anemia from marrow failure contributes to fatigue.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats),
        easy bleeding or bruising, fatigue, dyspnea and infection.
      explanation: >-
        Fatigue is directly reported, while the anemia-mediated causal route is
        clinically plausible but not isolated in the cited text and is therefore partial.
  - target: Recurrent Infections
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - leukopenia and reduced normal leukocyte function
    - impaired host defense
    description: Reduced effective normal leukocyte output increases susceptibility to infection.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats),
        easy bleeding or bruising, fatigue, dyspnea and infection.
      explanation: >-
        Infection is directly reported, while the leukopenia-mediated route is
        not experimentally isolated in the cited passage and is marked partial.
- name: Extramedullary Leukemic Involvement
  description: >-
    Lymphoblast accumulation outside marrow produces lymph-node, liver, spleen,
    CNS, or mediastinal findings. The mediastinal presentation is specifically
    scoped to T-ALL.
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Involvement of extramedullary sites commonly occurs and can cause
      lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients.
    explanation: >-
      The review directly links extramedullary involvement with lymph-node,
      spleen, and liver findings. The combined numerical estimate remains in
      the quotation and is not generalized into separate frequency fields.
  downstream:
  - target: Lymphadenopathy
    causal_link_type: DIRECT
    description: Leukemic involvement of lymph nodes produces lymphadenopathy.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Involvement of extramedullary sites commonly occurs and can cause
        lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients.
      explanation: The review directly states that extramedullary involvement can cause lymphadenopathy.
  - target: Hepatosplenomegaly
    causal_link_type: DIRECT
    description: Leukemic involvement of the liver or spleen produces organ enlargement.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Involvement of extramedullary sites commonly occurs and can cause
        lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients.
      explanation: The review directly states that extramedullary involvement can cause spleen or liver enlargement.
  - target: Central Nervous System Involvement
    causal_link_type: DIRECT
    description: Leukemic-cell involvement of the CNS produces neurologic or meningeal manifestations.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        CNS involvement at time of diagnosis occurs in 5–8% of patients and
        present most commonly as cranial nerve deficits or meningismus.
      explanation: The review directly reports CNS involvement and its usual presentations at diagnosis.
  - target: Mediastinal Mass
    causal_link_type: DIRECT
    description: T-lineage lymphoblast involvement can produce a mediastinal mass.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: T-cell ALL also may present with a mediastinal mass.
      explanation: The review directly supports the T-ALL-specific mediastinal presentation.

phenotypes:
- category: Hematologic
  name: Anemia
  description: >-
    Reduced effective erythropoiesis is one component of the marrow-failure
    presentation. No universal frequency band is assigned because the cited
    source does not provide a population estimate for anemia alone.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Presentation can be nonspecific, with a combination of constitutional
      symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
      leukopenia).
    explanation: The review directly identifies anemia as a marrow-failure sign in ALL.
- category: Hematologic
  name: Thrombocytopenia
  description: >-
    Reduced platelet production accompanies marrow failure and can contribute
    to bleeding or bruising. No unsourced frequency band is assigned.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Presentation can be nonspecific, with a combination of constitutional
      symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
      leukopenia).
    explanation: The review directly identifies thrombocytopenia as a marrow-failure sign in ALL.
- category: Hematologic
  name: Leukopenia
  description: >-
    Reduced normal leukocyte output is a marrow-failure finding even when the
    total circulating white-cell count is altered by lymphoblasts. No universal
    frequency band is assigned.
  phenotype_term:
    preferred_term: Leukopenia
    term:
      id: HP:0001882
      label: Decreased total leukocyte count
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Presentation can be nonspecific, with a combination of constitutional
      symptoms and signs of bone marrow failure (anemia, thrombocytopenia,
      leukopenia).
    explanation: The review directly identifies leukopenia as a marrow-failure sign in ALL.
- category: Hematologic
  name: Abnormal Bleeding or Bruising
  description: >-
    Easy bleeding or bruising can accompany the thrombocytopenic marrow-failure
    presentation. No universal frequency band is assigned.
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats),
      easy bleeding or bruising, fatigue, dyspnea and infection.
    explanation: The review directly reports easy bleeding or bruising among common ALL symptoms.
- category: Constitutional
  name: Fatigue
  description: >-
    Fatigue is a common constitutional presentation and may be compounded by
    anemia. No universal frequency band is assigned.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats),
      easy bleeding or bruising, fatigue, dyspnea and infection.
    explanation: The review directly reports fatigue among common ALL symptoms.
- category: Immune
  name: Recurrent Infections
  description: >-
    Infection can accompany impaired normal leukocyte production or function
    during marrow failure. No universal frequency band is assigned.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Common symptoms include ‘B symptoms’ (fever, weight loss, night sweats),
      easy bleeding or bruising, fatigue, dyspnea and infection.
    explanation: >-
      The source reports infection as a common symptom; it is partial support
      for the more specific recurrent-infections HPO representation.
- category: Lymphatic
  name: Lymphadenopathy
  description: >-
    Extramedullary lymph-node involvement can produce lymphadenopathy. The
    source gives a combined estimate for lymphadenopathy, splenomegaly, or
    hepatomegaly, so no separate frequency band is inferred.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Involvement of extramedullary sites commonly occurs and can cause
      lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients.
    explanation: >-
      The review directly links extramedullary involvement with
      lymphadenopathy; its combined percentage is not recast as a separate
      lymphadenopathy frequency.
- category: Abdominal
  name: Hepatosplenomegaly
  description: >-
    Leukemic involvement can enlarge the spleen, liver, or both. The source
    reports a combined group rather than a hepatosplenomegaly-specific rate, so
    no frequency band is assigned.
  phenotype_term:
    preferred_term: Hepatosplenomegaly
    term:
      id: HP:0001433
      label: Hepatosplenomegaly
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Involvement of extramedullary sites commonly occurs and can cause
      lymphadenopathy, splenomegaly or hepatomegaly in 20% of patients.
    explanation: >-
      The source directly supports liver or spleen enlargement; it is partial
      support for the combined HPO term.
- category: Neurologic
  name: Central Nervous System Involvement
  description: >-
    Leukemic CNS involvement at diagnosis can present with cranial-nerve
    deficits or meningismus. The reported percentage remains contextualized in
    the evidence rather than converted into a broad HPO frequency category.
  phenotype_term:
    preferred_term: Morphological central nervous system abnormality
    term:
      id: HP:0002011
      label: Morphological central nervous system abnormality
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      CNS involvement at time of diagnosis occurs in 5–8% of patients and
      present most commonly as cranial nerve deficits or meningismus.
    explanation: >-
      The review directly reports CNS involvement, while the available HPO term
      is broader than leukemia-specific CNS disease and is marked partial.
- category: Thoracic
  name: Mediastinal Mass
  subtype: T-ALL
  description: >-
    A mediastinal mass is a T-ALL-associated presentation and is not generalized
    to B-ALL. No universal frequency band is assigned.
  phenotype_term:
    preferred_term: Mediastinal mass
    term:
      id: HP:0033827
      label: Anterior mediastinal mass
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: T-cell ALL also may present with a mediastinal mass.
    explanation: The review directly supports a mediastinal mass as a T-ALL presentation.

biochemical:
- name: Measurable Residual Disease
  presence: VARIABLE
  notes: >-
    MRD is a post-treatment quantitative readout of residual leukemic burden,
    not a substitute for initial lineage and genomic diagnosis. Flow cytometry
    is established, while high-throughput clonotype sequencing can detect
    additional low-level disease in pediatric B-ALL. Results must be interpreted
    at protocol-defined time points and assay thresholds.
  readouts:
  - target: Common Lymphoblast Clonal Expansion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Detectable MRD after therapy reports persistence of the leukemic clone;
      lower or undetectable signal reports deeper response within the limits of
      the assay used.
    evidence:
    - reference: PMID:18388178
      reference_title: "Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The Children's Oncology Group studied the prognostic impact of MRD
        measured by flow cytometry in the peripheral blood at day 8, and in
        end-induction (day 29) and end-consolidation marrows in 2143 children
        with precursor B-cell ALL (B-ALL).
      explanation: >-
        The study directly supports flow-cytometric MRD as a timed post-treatment
        measurement of residual B-ALL burden.
  - target: Common Lymphoblast Clonal Expansion
    relationship: PREDICTS
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    interpretation: >-
      Detectable end-induction marrow MRD predicts worse event-free survival;
      this is a prognostic association and does not itself prove that MRD causes relapse.
    evidence:
    - reference: PMID:18388178
      reference_title: "Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis.
      explanation: >-
        The COG analysis directly supports day-29 marrow MRD as a prognostic
        predictor while the schema relationship remains noncausal.
  evidence:
  - reference: PMID:18388178
    reference_title: "Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of MRD in day-8 blood and day-29 marrow MRD was associated
      with shorter event-free survival (EFS) in all risk groups; even patients
      with 0.01% to 0.1% day-29 MRD had poor outcome compared with patients
      negative for MRD patients (59% +/- 5% vs 88% +/- 1% 5-year EFS).
    explanation: >-
      This large pediatric B-ALL cohort establishes the time-dependent
      prognostic significance of flow-cytometric MRD.
  - reference: PMID:29284596
    reference_title: Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The higher analytic sensitivity and lower false-negative rate of HTS
      improves upon FC for MRD detection in pediatric B-ALL by identifying a
      novel subset of patients at end of induction who are essentially cured
      using current chemotherapy and identifying MRD at 0.01% in up to
      one-third of patients who are missed at the same threshold by FC.
    explanation: >-
      The paired-sample study supports greater analytic sensitivity of
      high-throughput sequencing than flow cytometry in pediatric B-ALL without
      implying that the result applies unchanged to every ALL population.

genetic:
- name: BCR::ABL1 Fusion
  association: Defining kinase driver of Ph-positive B-ALL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: Ph-positive
  gene_term:
    preferred_term: ABL1
    term:
      id: hgnc:76
      label: ABL1
  notes: The t(9;22) lesion fuses BCR (hgnc:1014) to ABL1.
  evidence:
  - reference: PMID:41251904
    reference_title: "Philadelphia chromosome-positive acute lymphoblastic leukemia: exploring microRNA-based strategies to improve outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
      is characterized by the BCR::ABL1 fusion gene resulting from the
      translocation t(9;22).
    explanation: The source directly identifies the subtype-defining somatic fusion.
- name: KMT2A Rearrangement
  association: Defining rearrangement of KMT2A-rearranged B-ALL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: KMT2A-rearranged
  gene_term:
    preferred_term: KMT2A
    term:
      id: hgnc:7132
      label: KMT2A
  evidence:
  - reference: PMID:39261601
    reference_title: "Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short
      median time-to-relapse (12.5-18 months) and poor OS post-relapse
      (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%).
    explanation: >-
      The COG cohort treats KMT2A rearrangement as a recurrent subtype-defining
      lesion and reports its relapse context.
- name: ETV6::RUNX1 Fusion
  association: Defining fusion of ETV6::RUNX1 B-ALL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: ETV6-RUNX1
  gene_term:
    preferred_term: RUNX1
    term:
      id: hgnc:10471
      label: RUNX1
  notes: The fusion partner ETV6 is hgnc:3495.
  evidence:
  - reference: PMID:28418909
    reference_title: Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ETV6/RUNX1 (E/R) is the most common fusion gene in childhood acute
      lymphoblastic leukemia (ALL).
    explanation: The review directly supports ETV6::RUNX1 as a recurrent childhood ALL fusion.
- name: TCF3::PBX1 Fusion
  association: Defining fusion of TCF3::PBX1 B-ALL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: TCF3-PBX1
  gene_term:
    preferred_term: PBX1
    term:
      id: hgnc:8632
      label: PBX1
  notes: The fusion partner TCF3 is hgnc:11633.
  evidence:
  - reference: PMID:39261601
    reference_title: "Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short
      median time-to-relapse (12.5-18 months) and poor OS post-relapse
      (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%).
    explanation: The cohort supports TCF3::PBX1 as a recurrent genetic subtype.
- name: PAX5 Alterations
  association: Defining heterogeneous lesion class of PAX5-altered B-ALL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: PAX5-altered
  gene_term:
    preferred_term: PAX5
    term:
      id: hgnc:8619
      label: PAX5
  evidence:
  - reference: PMID:30643249
    reference_title: PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One, PAX5alt (7.4%), has diverse PAX5 alterations (rearrangements,
      intragenic amplifications or mutations); a second subtype is defined by
      PAX5 p.Pro80Arg and biallelic PAX5 alterations.
    explanation: >-
      Integrated genomics defines PAX5alt through heterogeneous somatic PAX5
      lesions rather than one uniform variant.
- name: NOTCH1 Activating Mutation
  association: Recurrent activating driver in T-ALL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: T-ALL
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  evidence:
  - reference: PMID:15472075
    reference_title: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report that more than 50% of human T-ALLs, including tumors from
      all major molecular oncogenic subtypes, have activating mutations that
      involve the extracellular heterodimerization domain and/or the C-terminal
      PEST domain of NOTCH1.
    explanation: >-
      The human tumor study directly supports recurrent activating somatic
      NOTCH1 mutations in T-ALL; no frequency field is generalized from it.
- name: IKZF1 Alteration
  association: Cooperating lesion and adverse-risk biomarker in B-ALL
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  subtype: B-ALL
  gene_term:
    preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  evidence:
  - reference: PMID:19129520
    reference_title: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic alteration of IKZF1 is associated with a very poor outcome in
      B-cell-progenitor ALL.
    explanation: >-
      The clinical cohort supports IKZF1 alteration as an adverse-risk
      cooperating biomarker rather than a defining lesion of all B-ALL.
- name: CDKN2A-CDKN2B Loss
  association: Recurrent cooperating checkpoint lesion in T-ALL
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  subtype: T-ALL
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  notes: The neighboring CDKN2B gene is hgnc:1788; the source refers to the shared INK4/ARF tumor-suppressor locus.
  evidence:
  - reference: PMID:28671688
    reference_title: The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic alterations that activate NOTCH1 signaling and T cell
      transcription factors, coupled with inactivation of the INK4/ARF tumor
      suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia
      (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has
      not been carried out.
    explanation: >-
      Integrated genomic evidence supports recurrent loss of the locus as a
      cooperating T-ALL pathway rather than a universal defining lesion.

diagnosis:
- name: Morphologic Blast Assessment and Flow-Cytometric Lineage Assignment
  diagnosis_term:
    preferred_term: flow cytometry procedure
    term:
      id: NCIT:C16585
      label: Flow Cytometry
  description: >-
    Initial diagnosis combines microscopic recognition of lymphoblasts with
    flow-cytometric immunophenotyping to assign B- or T-lineage and maturational
    stage. Neither morphology nor a single marker should be treated as a
    molecular subtype assignment.
  results: >-
    A lymphoblast population with a coherent precursor B- or T-lineage
    immunophenotype supports ALL in the appropriate marrow or blood context.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Morphological identification of lymphoblasts by microscopy and
      immunophenotypic determination of lineage commitment and developmental
      stage by flow cytometry are essential for correct diagnosis of ALL.
    explanation: >-
      The review directly supports the paired morphology and flow-cytometry
      workflow for lineage-aware initial diagnosis.
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diagnosis is established by the presence of 20% or more lymphoblasts in
      the bone marrow or peripheral blood.
    explanation: >-
      The review provides its stated blast threshold for a leukemic
      presentation; current entity-defining classification still requires
      integrated lineage and genomic interpretation.
- name: Cytogenetic and Molecular Subtype Assignment
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  description: >-
    Karyotype, cellular DNA-content assessment, FISH, fusion testing, and
    copy-number or sequencing assays identify subtype-defining rearrangements,
    aneuploidy, and cryptic lesions. The selected assay set must cover both
    established and newly recognized B- and T-ALL entities.
  results: >-
    A defining fusion, ploidy state, rearrangement, or molecular profile assigns
    the corresponding subtype and informs risk and targeted-treatment choices.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Chromosomal analysis still plays an important role in the initial
      cytogenetic work-up. RT-PCR, FISH/multiplex ligation-dependent probe
      amplification, and flow cytometry are used to identify leukaemia-specific
      translocations, submicroscopic chromosomal abnormalities, and cellular
      DNA content, respectively.
    explanation: >-
      The review directly supports complementary cytogenetic and molecular
      approaches to defining ALL lesions.
  - reference: PMID:38295337
    reference_title: "Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The European Working Group for Adult ALL has therefore summarized the
      current state of the art and provided comprehensive consensus
      recommendations for diagnostic approaches, biologic and clinical
      characterization, prognostic factors, and risk stratification as well as
      definitions of endpoints and outcomes.
    explanation: >-
      Current ELN consensus supports integrated diagnosis, biologic
      characterization, and risk stratification in adults.
- name: Post-Treatment MRD Response Assessment
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  description: >-
    Flow cytometry or clonotype-based high-throughput sequencing measures
    residual disease at protocol-defined response milestones. This is a
    monitoring and prognostic assessment after the initial diagnosis, not a
    replacement for lineage or subtype classification.
  results: >-
    Detectable residual leukemic cells or clonotypes quantify response depth
    and contribute to risk-adapted management, with assay-specific sensitivity
    and thresholds reported explicitly.
  evidence:
  - reference: PMID:18388178
    reference_title: "Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of MRD in day-8 blood and day-29 marrow MRD was associated
      with shorter event-free survival (EFS) in all risk groups
    explanation: >-
      Timed flow-cytometric MRD measurements carry prognostic information after
      therapy in pediatric precursor B-ALL.
  - reference: PMID:29284596
    reference_title: Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The higher analytic sensitivity and lower false-negative rate of HTS
      improves upon FC for MRD detection in pediatric B-ALL
    explanation: >-
      The paired-sample study supports high-throughput sequencing as a more
      analytically sensitive MRD method in its pediatric B-ALL context.

differential_diagnoses:
- name: Acute Myeloid Leukemia
  disease_term:
    preferred_term: acute myeloid leukemia
    term:
      id: MONDO:0018874
      label: acute myeloid leukemia
  description: >-
    AML can also present with an acute marrow blast process and cytopenias, so
    lineage must be assigned rather than inferred from morphology alone.
  distinguishing_features:
  - A coherent myeloid rather than precursor B- or T-lineage immunophenotype supports AML.
  - Integrated cytogenetic and molecular findings can identify an AML-defining entity.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Morphological identification of lymphoblasts by microscopy and
      immunophenotypic determination of lineage commitment and developmental
      stage by flow cytometry are essential for correct diagnosis of ALL.
    explanation: >-
      The source establishes lineage immunophenotyping as essential for ALL;
      its use here to distinguish an acute myeloid process is conservative and
      therefore marked partial.
- name: Mixed-Phenotype Acute Leukemia
  description: >-
    Mixed-phenotype acute leukemia enters the differential when the blast
    population meets lineage-defining criteria for more than one lineage or
    distinct blast populations establish different lineages.
  distinguishing_features:
  - Apply lineage-defining immunophenotypic criteria rather than labeling ambiguous marker expression as ALL.
  - Integrate recurrent fusion and cytogenetic results because they may alter entity assignment.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Morphological identification of lymphoblasts by microscopy and
      immunophenotypic determination of lineage commitment and developmental
      stage by flow cytometry are essential for correct diagnosis of ALL.
    explanation: >-
      The source supports explicit lineage assignment but does not enumerate
      mixed-phenotype criteria, so support is partial.
- name: Lymphoblastic Lymphoma
  description: >-
    Lymphoblastic lymphoma and ALL form a biologic spectrum. A tissue-predominant
    mass with limited marrow or blood disease favors the lymphoma designation,
    while a leukemic marrow or blood presentation favors ALL; classification
    should follow the applicable contemporary framework.
  distinguishing_features:
  - Establish the anatomic distribution and marrow or blood blast burden rather than relying on lineage alone.
  - Retain B- versus T-lineage and genomic subtype information across the leukemia-lymphoma spectrum.
  evidence:
  - reference: PMID:36422706
    reference_title: International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The updated International Consensus Classification (ICC) of B-acute
      lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL)
      includes both revisions to subtypes previously outlined in the 2016 WHO
      classification and several newly described entities.
    explanation: >-
      The ICC supports shared lineage and genomic taxonomy across
      ALL/lymphoblastic lymphoma, while the excerpt does not provide a numeric
      marrow boundary and is marked partial.

treatments:
- name: Risk-Adapted Multi-Agent Chemotherapy
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  role: Backbone therapy
  context: Regimen, intensity, and phase vary by age, lineage, molecular risk, MRD response, and protocol.
  description: >-
    Multi-agent induction followed by protocol-defined consolidation,
    intensification, and maintenance remains a treatment backbone. This entry
    deliberately avoids presenting one drug list, dose, remission percentage,
    or pediatric/adult regimen as universal across biologically and clinically
    heterogeneous ALL.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  target_mechanisms:
  - target: Common Lymphoblast Clonal Expansion
    treatment_effect: INHIBITS
    description: Cytotoxic combination therapy reduces the leukemic-cell burden and permits recovery of normal hematopoiesis.
    evidence:
    - reference: PMID:23523389
      reference_title: Acute lymphoblastic leukaemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Four to 6 weeks of remission-induction treatment eradicates the initial
        leukaemic cell burden and restores normal haematopoiesis in 96–99% of
        children and 78–92% of adults.
      explanation: >-
        The review directly connects induction treatment with reduced leukemic
        burden and restored hematopoiesis; its era- and population-specific
        response ranges remain contextual evidence rather than universal fields.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The chemotherapy agents typically include a glucocorticoid (prednisone
      or dexamethasone), vincristine, and asparaginase, with or without
      anthracycline.
    explanation: >-
      The review supports the multi-agent nature of induction while the entry
      defers exact composition and intensity to the applicable protocol.
  - reference: PMID:38306595
    reference_title: "Management of ALL in adults: 2024 ELN recommendations from a European expert panel."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The current recommendation summarizes clinical management. It covers
      treatment approaches, including the use of new immunotherapies,
      application of minimal residual disease for treatment decisions,
      management of specific subgroups, and challenging treatment situations as
      well as late effects and supportive care.
    explanation: >-
      Current adult ELN guidance supports treatment selection that integrates
      MRD, subgroup biology, difficult clinical contexts, and supportive care.
- name: CNS-Directed Intrathecal Chemotherapy
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  role: CNS prophylaxis or treatment
  context: Protocol-defined intrathecal therapy; intensity increases with CNS disease or other high-risk features.
  description: >-
    Intrathecal methotrexate-based combination therapy is used to prevent or
    control CNS leukemia. Cranial irradiation is not represented as a routine
    default because contemporary protocols often reduce or omit it to limit
    late toxicity.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  target_mechanisms:
  - target: Extramedullary Leukemic Involvement
    treatment_effect: INHIBITS
    description: Intrathecal therapy reduces or prevents leukemic burden in the CNS sanctuary compartment.
    evidence:
    - reference: PMID:23523389
      reference_title: Acute lymphoblastic leukaemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Control of CNS disease is a key component of ALL therapy.
      explanation: The review directly establishes CNS disease control as a core treatment objective.
  evidence:
  - reference: PMID:23523389
    reference_title: Acute lymphoblastic leukaemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      protocols replaced cranial irradiation with triple intrathecal chemotherapy
      (methotrexate, hydrocortisone, and cytarabine) for all newly diagnosed
      patients
    explanation: >-
      Protocol evidence supports triple intrathecal chemotherapy as a
      CNS-directed strategy while avoiding a claim that one schedule is universal.
- name: ABL-Directed Tyrosine Kinase Inhibitor Therapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  role: Molecularly targeted component
  context: Ph-positive B-ALL; agent and combination depend on mutation, prior therapy, toxicity, and protocol.
  description: >-
    ABL tyrosine-kinase inhibition is directed at the BCR::ABL1 dependency of
    Ph-positive B-ALL. Ponatinib retains activity against many kinase-domain
    resistance variants, but vascular and other toxicities require specialist
    selection and monitoring. Results from a single-centre phase 2 study of
    ponatinib plus blinatumomab are encouraging rather than proof that one combination
    should replace every established regimen.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: ponatinib
      term:
        id: CHEBI:78543
        label: ponatinib
  target_mechanisms:
  - target: Kinase-Activated B-ALL Signaling
    treatment_effect: INHIBITS
    description: ABL kinase inhibition suppresses BCR::ABL1-dependent signaling in Ph-positive B-ALL.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Ponatinib, a third-generation TKI with the ability to inhibit most
        BCR-ABL1 kinase domain mutations, has recently gained approval for
        resistant Ph-positive ALL.
      explanation: >-
        The review directly supports ponatinib-mediated inhibition across many
        BCR::ABL1 kinase-domain variants in resistant Ph-positive ALL.
  evidence:
  - reference: PMID:36402146
    reference_title: "Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The chemotherapy-free combination of ponatinib and blinatumomab resulted
      in high rates of complete molecular response in patients with newly
      diagnosed and relapsed or refractory Ph-positive acute lymphoblastic
      leukaemia.
    explanation: >-
      The phase 2 trial supports activity of the combination in its studied
      population; the entry explicitly retains the single-centre, single-arm limitation.
- name: Blinatumomab CD19-CD3 Bispecific Therapy
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  role: B-lineage immunotherapy
  context: Use depends on disease phase, antigen expression, MRD state, prior therapy, and protocol.
  description: >-
    Blinatumomab brings CD3-positive T cells into proximity with CD19-positive
    B-lineage blasts. Its established contexts include relapsed/refractory and
    MRD-directed use; E1910 additionally supports incorporation into
    consolidation for adults in MRD-negative remission from B-cell precursor ALL.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: blinatumomab
      term:
        id: NCIT:C62528
        label: Blinatumomab
  target_mechanisms:
  - target: Common Lymphoblast Clonal Expansion
    treatment_effect: INHIBITS
    description: CD19-CD3 engagement creates cytolytic synapses that kill CD19-positive B-lineage blasts.
    evidence:
    - reference: PMID:39047240
      reference_title: Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Blinatumomab is a bispecific T-cell engager molecule composed of an
        anti-CD19 variable region linked to an anti-CD3 variable region that
        brings T cells in proximity to leukemic blasts to form cytolytic
        synapses, leading to apoptosis and lysis of the blasts.
      explanation: The trial report directly states the CD19-CD3 cytolytic mechanism.
  evidence:
  - reference: PMID:39047240
    reference_title: Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The addition of blinatumomab to consolidation chemotherapy in adult
      patients in MRD-negative remission from BCP-ALL significantly improved
      overall survival.
    explanation: >-
      Randomized E1910 evidence supports consolidation blinatumomab in the
      explicitly stated adult MRD-negative remission population.
- name: Inotuzumab Ozogamicin CD22-Directed Therapy
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  role: B-lineage antibody-drug conjugate
  context: Relapsed or refractory CD22-positive B-lineage ALL; hepatotoxicity and transplant sequencing require specialist management.
  description: >-
    Inotuzumab ozogamicin binds CD22 and delivers calicheamicin intracellularly,
    causing DNA double-strand breaks and apoptosis. Its relapsed/refractory
    benefit must be balanced against serious toxicities, including hepatic
    veno-occlusive disease reported in trials.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: inotuzumab ozogamicin
      term:
        id: NCIT:C71542
        label: Inotuzumab Ozogamicin
  target_mechanisms:
  - target: Common Lymphoblast Clonal Expansion
    treatment_effect: INHIBITS
    description: CD22-mediated internalization delivers calicheamicin to B-lineage blasts and induces apoptotic DNA damage.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Inotuzumab ozogamicin (InO) is a monoclonal antibody against CD22 that
        is conjugated to calicheamicin, a potent cytotoxic compound that induces
        double-strand DNA breaks.
      explanation: The review directly supports CD22 targeting and the conjugated cytotoxic mechanism.
  evidence:
  - reference: PMID:27292104
    reference_title: Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rate of complete remission was significantly higher in the inotuzumab
      ozogamicin group than in the standard-therapy group
    explanation: >-
      Randomized phase 3 evidence supports superior remission rates in adults
      with relapsed or refractory ALL; the population and endpoint remain explicit.

- name: Tisagenlecleucel CD19 CAR-T Cell Therapy
  action_category: THERAPEUTIC
  therapeutic_modality: CELL_THERAPY
  role: Autologous cellular immunotherapy
  context: Pediatric and young adult relapsed or refractory B-cell ALL within authorized and specialist-program criteria.
  description: >-
    Autologous T cells engineered with a CD19-directed chimeric antigen receptor
    can expand and persist after infusion and produce durable remissions in
    relapsed or refractory B-cell ALL. Cytokine-release syndrome, neurologic
    toxicity, B-cell aplasia, manufacturing feasibility, and eligibility
    require specialist management.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: tisagenlecleucel
      term:
        id: NCIT:C102758
        label: Tisagenlecleucel
  target_mechanisms:
  - target: Common Lymphoblast Clonal Expansion
    treatment_effect: INHIBITS
    description: CD19-directed CAR T cells recognize and eliminate CD19-positive B-lineage blasts.
    evidence:
    - reference: PMID:29385370
      reference_title: Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In this global study of CAR T-cell therapy, a single infusion of
        tisagenlecleucel provided durable remission with long-term persistence
        in pediatric and young adult patients with relapsed or refractory
        B-cell ALL, with transient high-grade toxic effects.
      explanation: >-
        The global multicentre study supports durable remission and cellular
        persistence in the explicitly scoped pediatric and young-adult population.
  evidence:
  - reference: PMID:29385370
    reference_title: Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this global study of CAR T-cell therapy, a single infusion of
      tisagenlecleucel provided durable remission with long-term persistence in
      pediatric and young adult patients with relapsed or refractory B-cell ALL,
      with transient high-grade toxic effects.
    explanation: >-
      This supports tisagenlecleucel efficacy and also preserves the reported
      high-grade-toxicity qualification.
- name: Investigational Allogeneic CD19 CAR-T Cell Therapy (Phase 1)
  action_category: THERAPEUTIC
  therapeutic_modality: CELL_THERAPY
  role: Investigational phase 1 therapy
  context: Small single-arm phase 1 cohort in relapsed or refractory B-cell ALL; not established standard care.
  description: >-
    A non-gene-edited allogeneic CD19 CAR-T product showed early antileukemic
    activity without observed graft-versus-host disease in a very small phase 1
    study. The cohort size, single-arm design, toxicities, and limited survival
    estimates preclude treating this approach as established or equivalent to
    authorized autologous CAR-T therapy.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
  target_mechanisms:
  - target: Common Lymphoblast Clonal Expansion
    treatment_effect: INHIBITS
    description: Donor-derived CD19-directed CAR T cells are intended to eliminate CD19-positive B-lineage blasts.
    evidence:
    - reference: PMID:42237011
      reference_title: "Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        At day 28, 8 of 9 evaluable patients achieved complete remission (CR)
        or CR with incomplete hematologic recovery (CRi).
      explanation: >-
        The small phase 1 cohort provides early clinical activity consistent
        with blast elimination but does not establish comparative efficacy.
  evidence:
  - reference: PMID:42237011
    reference_title: "Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No GVHD was observed.
    explanation: >-
      Absence of observed GVHD in this tiny cohort is a safety observation, not
      proof that the platform eliminates GVHD risk.
  - reference: PMID:42237011
    reference_title: "Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At day 28, 8 of 9 evaluable patients achieved complete remission (CR) or
      CR with incomplete hematologic recovery (CRi).
    explanation: >-
      The response result is explicitly contextualized as nine evaluable
      patients in an open-label, single-arm phase 1 study.
- name: Nelarabine-Containing Therapy for T-ALL
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  role: T-lineage-directed chemotherapy component
  context: T-ALL; frontline incorporation or relapsed/refractory use depends on age, protocol, prior therapy, and neurotoxicity risk.
  description: >-
    Nelarabine is converted to a purine nucleoside analogue that preferentially
    accumulates in T cells, incorporates into DNA, inhibits DNA synthesis, and
    induces apoptosis. Randomized AALL0434 evidence supports its addition to an
    augmented BFM backbone in children and young adults with newly diagnosed T-ALL.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Common Lymphoblast Clonal Expansion
    treatment_effect: INHIBITS
    description: DNA incorporation inhibits synthesis and induces apoptosis in T-lineage lymphoblasts.
    evidence:
    - reference: PMID:28665419
      reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Nelarabine accumulates in T cells at a high rate and incorporates into
        DNA causing an inhibition of DNA synthesis and subsequent apoptosis.
      explanation: The review directly states the T-cell-selective cytotoxic mechanism.
  evidence:
  - reference: PMID:32813610
    reference_title: "Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The addition of nelarabine to ABFM therapy improved DFS for children and
      young adults with newly diagnosed T-ALL without increased toxicity.
    explanation: >-
      Randomized phase 3 evidence supports addition of nelarabine in the
      specified pediatric and young-adult frontline context.
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  action_category: THERAPEUTIC
  therapeutic_modality: CELL_THERAPY
  role: Selected high-risk or relapsed-disease consolidation
  context: Eligibility and timing depend on age, comorbidity, remission, MRD, genotype, donor, prior therapy, and protocol.
  description: >-
    Allogeneic transplantation is reserved for selected patients rather than
    applied uniformly across ALL. The balance among relapse risk, transplant
    morbidity and mortality, modern immunotherapies, and MRD response requires
    protocol- and patient-specific assessment.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:28665419
    reference_title: "Acute lymphoblastic leukemia: a comprehensive review and 2017 update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Despite advances in management, the backbone of therapy remains
      multi-agent chemotherapy with vincristine, corticosteroids and an
      anthracycline with allogeneic stem cell transplantation for eligible candidates.
    explanation: >-
      The review supports transplantation for eligible patients, while current
      selection has evolved and is therefore represented cautiously as partial support.
  - reference: PMID:38306595
    reference_title: "Management of ALL in adults: 2024 ELN recommendations from a European expert panel."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It covers treatment approaches, including the use of new immunotherapies,
      application of minimal residual disease for treatment decisions,
      management of specific subgroups, and challenging treatment situations as
      well as late effects and supportive care.
    explanation: >-
      Current ELN guidance supports integrating MRD, newer immunotherapy, and
      subgroup context into adult treatment decisions; the abstract does not
      state a universal transplant indication.
- name: Supportive and Toxicity-Directed Care
  action_category: THERAPEUTIC
  therapeutic_modality: OTHER
  role: Supportive care throughout treatment
  context: Individualized infection, transfusion, tumor-lysis, thrombosis, organ-toxicity, fertility, psychosocial, and survivorship management.
  description: >-
    ALL treatment requires preventive and responsive supportive care across
    induction, consolidation, immunotherapy, transplantation, and follow-up.
    Exact interventions depend on current counts, organ function, regimen,
    toxicities, infection risk, and local standards.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:38306595
    reference_title: "Management of ALL in adults: 2024 ELN recommendations from a European expert panel."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The current recommendation summarizes clinical management. It covers
      treatment approaches, including the use of new immunotherapies,
      application of minimal residual disease for treatment decisions,
      management of specific subgroups, and challenging treatment situations as
      well as late effects and supportive care.
    explanation: >-
      Current adult ELN recommendations explicitly include supportive care and
      late effects within comprehensive ALL management.

classifications:
  icdo_morphology:
    classification_value: Leukemia
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
datasets:
- accession: ega:EGAS00001000246
  title: Genetic landscape of pediatric Infant Acute Lymphoblastic leukemia
  description: We performed whole genome sequencing of tumor and normal DNA samples obtained from 22 infant ALL cases with MLL rearrangements. In addition, we sequenced 2 paired diagnostic-relapse samples. Using complementary pipelines, somatically acquired genetic changes were analyzed, including single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the cancer genomes. In addition, exome sequencing was performed on paired diagnostic and normal DNA samples obtained from 20 cases of non-infant MLL rearranged leukemias and somatic mutations in the coding regions were identified.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Acute Lymphoblastic Leukemia"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000253
  title: Whole genome sequencing of pediatric BCR-ABL1 positive acute lymphoblastic leukemia
  description: We performed whole-genome sequencing of 18 paired tumor/normal BCR-ABL1+ leukemia genomes and analyzed single nucleotide variations (SNVs), insertion/deletions, structural variations and copy number variations in the tumor and normal genomes
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Acute Lymphoblastic Leukemia"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000296
  title: Exome sequencing identifies mutation of the ribosome in T-cell acute lymphoblastic leukemia
  description: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and responds well to therapy in children, but not in adults. We used exome sequencing of 67 T-cell ALL (T- ALL) samples to gain insight in the mutational spectrum and age related differences of these leukemias. We detected protein-altering mutations in 508 genes, with an average of 8.2 mutations in pediatric and 21.0 in adult T-ALL. Based on stringent filtering, we predict 15 of these genes to be drivers, including 7 genes that were not previously implicated in T-ALL.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WES
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Acute Lymphoblastic Leukemia"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST002383
  title: Metabolomics of B-cell Acute Lymphoblastic Leukemia in Response to Adipocyte Conditioned Media
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Acute Lymphoblastic Leukemia"). Retrieved 2026-08-02.
- accession: massive:MSV000084862
  title: Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia
  description: Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Acute Lymphoblastic Leukemia"). Retrieved 2026-08-02.

📚

References & Deep Research

Deep Research

2

Falcon ▸

1. Disease Information

Edison Scientific Literature 58 citations 2026-05-12T14:54:12.027090

1. Disease Information

1.1 Concise overview

Acute lymphoblastic leukemia/lymphoma (ALL) is an aggressive neoplasm of precursor B‑ or precursor T‑lymphoid cells (B‑ALL and T‑ALL) that typically arises in the bone marrow but can involve extramedullary sites. (duffield2023internationalconsensusclassification pages 1-3, kansal2023diagnosisandmolecular pages 1-2)

Modern classification is genetics-forward. WHO 2022 (WHO‑HAEM5) and the International Consensus Classification (ICC) incorporate molecular/cytogenetic entities and transcriptome-defined subgroups to refine diagnosis and risk stratification. (kansal2023diagnosisandmolecular pages 5-7, duffield2023internationalconsensusclassification pages 1-3, yoon2024diagnosticandtherapeutic pages 1-2)

1.2 Synonyms / alternative names

Acute lymphocytic leukemia (older/common)
B‑lymphoblastic leukemia/lymphoma (B‑ALL/LBL)
T‑lymphoblastic leukemia/lymphoma (T‑ALL/LBL)
“Precursor B/T lymphoblastic leukemia/lymphoma” (older WHO terminology) (kansal2023diagnosisandmolecular pages 5-7, kansal2023diagnosisandmolecular pages 4-5)

1.3 Evidence provenance

The report primarily synthesizes aggregated disease-level resources (2024 ELN recommendations; 2024 NCCN guideline excerpt; 2023 ICC classification paper; 2024 population studies and clinical trials) plus selected human cohort/clinical trial primary studies (SEER analyses; prospective phase 2; JCO trial update). (gokbuget2024managementofall pages 1-2, shah2024acutelymphoblasticleukemia pages 1-2, duffield2023internationalconsensusclassification pages 1-3, liu2024epidemiologicalcharacteristicsand pages 1-3, lu2024reduceddosechemotherapyand pages 1-2, kantarjian2024resultsofthe pages 1-3)

2. Etiology

2.1 Disease causal factors (current understanding)

ALL is initiated and driven by acquired genetic lesions in lymphoid precursors (e.g., chromosomal rearrangements creating oncogenic fusions; aneuploidy; activating kinase lesions), with additional cooperating mutations and epigenetic remodeling. WHO‑HAEM5/ICC increasingly define ALL entities by such genomic features, including transcriptome-defined classes for previously “B‑other” cases. (kansal2023diagnosisandmolecular pages 5-7, duffield2023internationalconsensusclassification pages 1-3)

2.2 Risk factors

Genetic susceptibility / predisposition

A 2023 pediatric-focused review summarizes that germline susceptibility includes common loci (e.g., ARID5B, CEBPE, BMI1, CDKN2A/2B) and rare inherited mutations in hematopoietic genes (ETV6, PAX5, IKZF1). It reports ~4.4% of children/adolescents with ALL carry pathogenic germline mutations in known cancer genes, and that Down syndrome confers ~20‑fold increased risk. (ekpa2023areviewof pages 2-3)

Environmental and demographic risk factors

Ionizing radiation, male sex, high birth weight are cited as recognized/established risk factors in a 2024 SEER-based ecological analysis context. (little2024solarultravioletradiation pages 1-2)
Ambient solar ultraviolet radiation (UVR): A 2024 SEER-based population study reported a statistically significant association between higher ambient UVR irradiance and childhood ALL incidence (RR = 1.200 per mW/cm²; p = 0.004), and a borderline trend for cumulative radiant exposure (RR = 1.444 per MJ/cm²; p = 0.0865), with stronger effects in ages 0–3 and among Hispanic children. The authors conclude the finding “is not clear-cut, and in need of replication.” (little2024solarultravioletradiation pages 1-2, little2024solarultravioletradiation pages 8-9)

Visual evidence (RR vs UVR): Figure showing the RR relationship used in this analysis is provided in (little2024solarultravioletradiation media 5ae23b8e).

Obesity (prognostic/biologic determinant in adults): A 2024 adult cohort study found higher BMI at diagnosis was independently associated with worse overall survival (OS) (HR 10.3, 95% CI 2.56–41.5), and was associated with higher frequency of BCR::ABL1 (Ph+) (OR 7.64, 95% CI 1.17–49.9). (johnston2024socioeconomicdeterminantsof pages 1-2)

2.3 Protective factors

No specific protective genetic variants or protective exposures were directly extractable from the retrieved evidence set. The UVR literature is mixed (some prior work suggests protection with higher solar exposure, but the 2024 US SEER ecological study reported the opposite direction for ALL). (little2024solarultravioletradiation pages 8-9)

2.4 Gene–environment interactions

Direct GxE analyses were not present in the retrieved corpus. However, a 2023 pediatric review highlights maternal exposures (tobacco smoke, air pollution, BMI) being associated with neonatal DNA methylation changes, suggesting a plausible epigenetic mediation pathway for environmental effects on leukemia risk. (ekpa2023areviewof pages 2-3)

3. Phenotypes

3.1 Common presenting symptoms/signs (human clinical)

A 223-case pediatric clinicopathological series provides concrete presentation frequencies: - Pallor/anemia: 93.3% (208/223) - Fever: 89.7% (200/223) - Hepatomegaly: 89.2% (199/223) - Splenomegaly: 74.9% (167/223) - Lymphadenopathy: 63.7% (142/223) - Bony tenderness/bone pain: 50.7% (113/223) - Bleeding manifestations: 35.9% - Joint involvement/arthritis-like: 25.6% - CNS involvement at diagnosis: ~1.3% - Testicular enlargement: ~0.44% (karim2023diagnosticclueof pages 2-4)

A 2024 musculoskeletal-mimic report/review context also emphasizes that 15–30% of ALL cases may present with isolated, persistent osteo‑articular complaints that can delay diagnosis and can be masked by corticosteroids. (talukder2024acutelymphoblasticleukemia pages 1-3, karim2023diagnosticclueof pages 5-6)

3.2 Laboratory abnormalities (human clinical)

From the same 223-case series: - Leukocytosis: 49.4% (including WBC >50,000/µL in 24.2%; WBC >100,000/µL in 15.2%) - Leukopenia: 18.8% - Pancytopenia at diagnosis: 18.8% - Decreased age-adjusted neutrophil percentage: 93.7% (karim2023diagnosticclueof pages 2-4, karim2023diagnosticclueof pages 1-2)

3.3 Suggested HPO terms (examples)

(Provide as starting points; exact mapping may be adjusted during ontology curation.) - Fever HP:0001945 - Pallor HP:0000980 - Anemia HP:0001903 - Thrombocytopenia HP:0001873; Bleeding tendency HP:0001892 - Neutropenia HP:0001875; Leukocytosis HP:0001974; Leukopenia HP:0001882; Pancytopenia HP:0001876 - Hepatomegaly HP:0002240; Splenomegaly HP:0001744 - Lymphadenopathy HP:0002716 - Bone pain HP:0002653; Bone tenderness HP:0030830 - Arthritis/Joint pain HP:0001369 - CNS involvement can manifest as headache HP:0002315, cranial nerve palsy HP:0001291 (clinical term selection depends on documentation). (karim2023diagnosticclueof pages 2-4)

3.4 Quality of life impact

While the retrieved evidence set did not include formal QoL instrument outcomes, the phenotype spectrum above implies substantial functional impact via fatigue, pain, infection risk, and bleeding risk, and treatment is associated with significant toxicity; ELN 2024 explicitly includes supportive care and late effects in its scope. (gokbuget2024managementofall pages 1-2)

4. Genetic / Molecular Information

4.1 Core disease genes and recurrent abnormalities (somatic)

WHO‑HAEM5/ICC classify many ALL entities by recurrent genetic lesions. Examples explicitly discussed in the retrieved evidence include: - BCR::ABL1 (Philadelphia chromosome) / Ph+ ALL and BCR::ABL1‑like (“Ph‑like”) (yoon2024diagnosticandtherapeutic pages 1-2, kansal2023diagnosisandmolecular pages 5-7) - ETV6::RUNX1, TCF3::PBX1, KMT2A (MLL) rearrangements, aneuploidy classes (high hyperdiploidy, hypodiploidy), and newer entities derived from genomic/transcriptome profiling previously within “B‑other”. (kansal2023diagnosisandmolecular pages 5-7, kansal2023diagnosisandmolecular pages 4-5)

The ICC 2022 framework further subdivides BCR::ABL1+ cases (lymphoid-only vs multilineage) and introduces multiple new genetic categories and provisional gene-expression-defined entities. (duffield2023internationalconsensusclassification pages 1-3)

4.2 Germline predisposition genes (examples)

ETV6, PAX5, IKZF1 (rare inherited mutations) and common susceptibility loci (e.g., ARID5B) are summarized in the 2023 pediatric review. (ekpa2023areviewof pages 2-3)

4.3 Epigenetics

The 2023 pediatric review highlights epigenome-wide associations of maternal exposures (e.g., smoking) with neonatal methylation changes (e.g., AHRR CpG cg05575921), consistent with epigenetic mediation hypotheses for leukemia risk. (ekpa2023areviewof pages 2-3)

5. Environmental Information

5.1 Environmental factors

Ionizing radiation is cited as a recognized risk factor in recent epidemiology context. (little2024solarultravioletradiation pages 1-2)
Ambient UVR is under active investigation; a large 2024 ecological analysis suggests increased childhood ALL risk with higher ambient UVR (RR effect sizes above). (little2024solarultravioletradiation pages 1-2, little2024solarultravioletradiation media 5ae23b8e)

5.2 Lifestyle factors

Obesity emerges as a prognostic/biologic determinant of adverse OS in adults with ALL in a 2024 center cohort. (johnston2024socioeconomicdeterminantsof pages 1-2)

5.3 Infectious agents

Direct pathogen causation is not established for ALL in general; infection-related hypotheses (population mixing/delayed infection) are discussed as etiologic theories in pediatric literature. (ekpa2023areviewof pages 2-3, little2024solarultravioletradiation pages 11-11)

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

1) Initiating lesions (chromosomal rearrangements/aneuploidy/kinase activation) occur in developing lymphoid precursors. (kansal2023diagnosisandmolecular pages 5-7, duffield2023internationalconsensusclassification pages 1-3) 2) Differentiation arrest and uncontrolled proliferation yield expanding lymphoblast clones in marrow and/or extramedullary sites. A 2024 adult review describes ALL as “marked by abnormal clones with arrested differentiation and uncontrolled proliferation in bone marrow and extramedullary sites.” (yoon2024diagnosticandtherapeutic pages 1-2) 3) Marrow failure causes cytopenias (anemia → pallor/fatigue; thrombocytopenia → bleeding; neutropenia → infection/fever) and may coexist with leukocytosis and circulating blasts. (karim2023diagnosticclueof pages 2-4) 4) Tissue infiltration produces hepatosplenomegaly, lymphadenopathy, bone pain/periosteal involvement, and less commonly CNS/testicular disease. (karim2023diagnosticclueof pages 2-4)

6.2 Pathway-level themes (from subtype concepts)

The retrieved WHO‑HAEM5/ICC sources emphasize that subtypes are increasingly organized around: - Kinase signaling activation (e.g., BCR::ABL1 and Ph‑like lesions), affecting therapy selection (TKIs; immunotherapy-based regimens) and risk. (yoon2024diagnosticandtherapeutic pages 1-2, kantarjian2024ponatinib‐reviewofhistorical pages 10-11) - Transcription factor and developmental programs identified by gene-expression clustering (ICC) that refine biologic taxonomy beyond classical cytogenetics. (duffield2023internationalconsensusclassification pages 1-3)

6.3 Suggested GO / CL terms (examples)

GO biological processes:
GO:0007049 cell cycle; GO:0008283 cell population proliferation; GO:0006915 apoptotic process; GO:0042127 regulation of cell population proliferation.
CL cell types:
CL:0000816 B cell; CL:0000542 lymphocyte; CL:0000792 T cell.
For leukemia blasts: “lymphoblast” is not always a CL term; practical annotation may use precursor B/T cell terms plus “neoplastic cell”.

7. Anatomical Structures Affected

7.1 Organ/tissue level

Primary site is the bone marrow with systemic hematopoietic involvement; common secondary involvement includes liver, spleen, lymph nodes, and bone (pain/tenderness). Less commonly at diagnosis: CNS and testis. (karim2023diagnosticclueof pages 2-4)

7.2 Suggested UBERON terms (examples)

Bone marrow UBERON:0002371
Liver UBERON:0002107
Spleen UBERON:0002106
Lymph node UBERON:0000029
Central nervous system UBERON:0001016
Testis UBERON:0000473 (karim2023diagnosticclueof pages 2-4)

8. Temporal Development

8.1 Onset

ALL has a strong pediatric incidence peak but occurs across the lifespan. Median age at diagnosis in the US is 17 years, with 53.5% diagnosed before age 20. (shah2024acutelymphoblasticleukemia pages 1-2)

8.2 Progression and course

Clinically acute presentation is typical; untreated disease progresses rapidly with complications from cytopenias and infiltration. Response and relapse risk are strongly influenced by molecular subtype and depth of remission measured by MRD. (gokbuget2024managementofall pages 6-6)

9. Inheritance and Population

9.1 Epidemiology (recent statistics)

US incidence: age-adjusted incidence 1.8 per 100,000 per year; estimated 6,550 new cases and 1,330 deaths in 2024 (NCCN excerpt). (shah2024acutelymphoblasticleukemia pages 1-2)
Age distribution: 53.5% diagnosed <20; 29.6% ≥45; 13.7% ≥65. (shah2024acutelymphoblasticleukemia pages 1-2)
SEER trend analysis: From 2000–2016, childhood/adolescent ALL incidence APC 1.5% (95% CI 1.1–1.8); adult ALL incidence APC 2.5% (95% CI 2.0–3.1). (liu2024epidemiologicalcharacteristicsand pages 1-3)

9.2 Heritability/inheritance

Most ALL is sporadic (somatic). A minority reflects germline predisposition syndromes/variants (e.g., Down syndrome and inherited variants in ETV6/PAX5/IKZF1). (ekpa2023areviewof pages 2-3)

10. Diagnostics

10.1 Core diagnostic modalities

Morphology plus immunophenotyping (flow cytometry or immunohistochemistry) to establish lymphoblastic lineage. (kansal2023diagnosisandmolecular pages 4-5)
Cytogenetic and molecular profiling to assign WHO‑HAEM5/ICC genetic subtype (e.g., BCR::ABL1, aneuploidy classes, fusion-defined entities; transcriptome-defined subtypes). (kansal2023diagnosisandmolecular pages 5-7, duffield2023internationalconsensusclassification pages 1-3)

10.2 MRD (measurable/minimal residual disease): methods, thresholds, timing

MRD is central to prognosis and therapeutic decision-making in adult ALL. - Threshold commonly used: 0.01% (10−4), aligned to typical assay sensitivity; ELN notes each log increase in MRD shortens time to hematologic relapse. (gokbuget2024managementofall pages 6-6) - Method performance: - Expert review: RQ‑PCR sensitivity ~10−5; multiparametric flow cytometry ~10−4; PCR/HTS may reach ~10−6 depending on input. (sebastian2024howitreat pages 1-2, yoon2024diagnosticandtherapeutic pages 6-8) - Timing: ELN emphasizes early vs later MRD timepoints (often ~2–3 months) to guide escalation/de‑escalation. (gokbuget2024managementofall pages 6-6)

10.3 Guideline risk criteria examples

NCCN excerpt includes traditional high-risk features in one trial framework: age ≥35 years, time to CR >4 weeks, or high WBC (>30×10^9/L for B-lineage; >100×10^9/L for T-lineage). (shah2024acutelymphoblasticleukemia pages 3-5)

11. Outcome / Prognosis

11.1 Survival highlights (recent/referenced)

Pediatric outcomes are substantially better than adult outcomes overall. A 2024 SEER-based analysis states pediatric survival is ~90% while older adult survival (55–70 years) is ~30–40% (contextual summary). (ghosh2024incidenceandsurvivability pages 1-3)
ELN/MRD: MRD-positive status is associated with markedly higher relapse risk; one 2024 review reports 5‑year hematologic relapse 56–100% if MRD+ vs 18–33% if MRD−. (stelljes2024ph−allimmunotherapy pages 1-2)

11.2 Prognostic factors (examples)

MRD level and kinetics are among the strongest predictors and guide allo-HCT selection. (gokbuget2024managementofall pages 6-6)
Age and obesity are independent adverse predictors of OS in an adult cohort; higher BMI also associated with BCR::ABL1 positivity. (johnston2024socioeconomicdeterminantsof pages 1-2)

12. Treatment

12.1 Current applications and real-world implementation (2024 consensus)

The 2024 European LeukemiaNet (ELN) recommendations emphasize risk-adapted adult ALL management driven by baseline prognostic factors and MRD to determine intensity, incorporation of immunotherapies, and transplant indications. (gokbuget2024managementofall pages 1-2)

12.2 Key modalities, evidence, and 2024 trial statistics

Modality/agent	Target or mechanism	Key use-case	Selected 2024 efficacy/statistics	Key toxicities / implementation notes	Key 2024 sources with URL and pub month/year
Pediatric-inspired multi-agent chemotherapy (adult AYA/fit adults); e.g., pediatric-inspired regimens, Hyper-CVAD variants	Multi-agent cytotoxic therapy targeting proliferating lymphoblasts; often includes asparaginase, vincristine, steroids, anthracycline, methotrexate/6-MP phases	Standard frontline backbone for Ph-negative ALL in younger/fit adults; adapted intensity by age/fitness	ELN 2024: pediatric-based regimens are standard up to ~45–55 years and adult Ph-negative ALL CR rates are ~90% in many groups; expert review notes ~20% 5-year OS benefit in AYA with pediatric-inspired regimens vs traditional adult regimens (gokbuget2024managementofall pages 1-2, sebastian2024howitreat pages 1-2)	Age/fitness constrained; asparaginase toxicity, infections, hepatic/pancreatic toxicity, thrombosis; obesity adversely affects OS in adults and may shape supportive-care intensity (sebastian2024howitreat pages 1-2, johnston2024socioeconomicdeterminantsof pages 1-2)	Gökbuget et al., Blood (May 2024) https://doi.org/10.1182/blood.2023023568 (gokbuget2024managementofall pages 1-2); Sebastian, Clin Hematol Int (May 2024) https://doi.org/10.46989/001c.117026 (sebastian2024howitreat pages 1-2); Johnston et al., Blood Adv (Dec 2024) https://doi.org/10.1182/bloodadvances.2023011862 (johnston2024socioeconomicdeterminantsof pages 1-2)
TKIs for Ph+ ALL (imatinib, dasatinib, ponatinib)	Inhibit BCR::ABL1 kinase signaling; ponatinib active against T315I and other resistant mutants	Frontline Ph+ ALL; often with reduced-intensity chemo or with blinatumomab; salvage/bridge contexts also used	Ponatinib review: PONALFIL post-induction CMR 47% rising to 71% in consolidation; 3-year OS 97%, EFS 70%; PhALLCON MRD-negative CR 34.4% with ponatinib vs 16.7% imatinib, and in age ≥60 years 40.0% vs 10.3%, median PFS 22.5 vs 8.3 months (kantarjian2024ponatinib‐reviewofhistorical pages 10-11)	Cardiovascular/arterial occlusive risk with ponatinib; pancreatitis reported; TKI selection depends on mutation profile, age, comorbidities, CNS strategy, transplant plan (kantarjian2024ponatinib‐reviewofhistorical pages 10-11, sebastian2024howitreat pages 5-7)	Kantarjian et al., Am J Hematol (May 2024) https://doi.org/10.1002/ajh.27355 (kantarjian2024ponatinib‐reviewofhistorical pages 10-11); Sebastian, Clin Hematol Int (May 2024) https://doi.org/10.46989/001c.117026 (sebastian2024howitreat pages 5-7)
Blinatumomab	CD19xCD3 bispecific T-cell engager; redirects T cells to lyse CD19+ B-ALL cells	MRD-positive B-ALL; R/R B-ALL; increasingly frontline consolidation/low-intensity induction component in Ph-negative and Ph+ disease	Frontline Ph-negative phase 2 (reduced-dose chemo → blinatumomab): CRc 94% after 2 weeks blina, MRD-negative 86%; with up to 4 weeks, CR 100% and MRD-negative 89%; 1-year OS 97.1%, PFS 82.2% (NCT05557110) (lu2024reduceddosechemotherapyand pages 1-2). Review/guideline: MRD response ~80% and hematologic relapse-free survival 61% in MRD-directed setting; survival benefit also emerging in MRD-negative frontline consolidation (stelljes2024ph−allimmunotherapy pages 1-2)	Continuous IV infusion standard; CRS and neurotoxicity/ICANS require monitoring; in Lu 2024 ICANS 14% (all grade 1), grade ≥3 CRS 9% (lu2024reduceddosechemotherapyand pages 1-2)	Lu et al., J Hematol Oncol (Sep 2024) https://doi.org/10.1186/s13045-024-01597-8 (lu2024reduceddosechemotherapyand pages 1-2); Stelljes, Hematology (Dec 2024) https://doi.org/10.1182/hematology.2024000531 (stelljes2024ph−allimmunotherapy pages 1-2); Gökbuget et al., Blood (May 2024) https://doi.org/10.1182/blood.2023023568 (gokbuget2024managementofall pages 1-2)
Inotuzumab ozogamicin	Anti-CD22 antibody-drug conjugate delivering calicheamicin	Approved for R/R CD22+ B-ALL; increasingly used in frontline low-intensity regimens in older/unfit adults; MRD eradication / bridge to HSCT / sequencing with CAR-T	2024 reviews summarize strong efficacy in R/R disease and promising frontline combinations with low-intensity chemotherapy or blinatumomab; used to eliminate MRD and bridge to HSCT/CAR-T, but article excerpt does not provide one uniform 2024 pooled ORR/OS estimate across settings (kantarjian2024inotuzumabozogamicinin pages 15-17, gokbuget2024managementofall pages 21-22)	Key risk is veno-occlusive disease/sinusoidal obstruction syndrome, especially pre-HSCT; fractionated dosing and transplant timing matter (kantarjian2024inotuzumabozogamicinin pages 15-17)	Kantarjian et al., Cancer (Aug 2024) https://doi.org/10.1002/cncr.35505 (kantarjian2024inotuzumabozogamicinin pages 15-17); Gökbuget et al., Blood (May 2024) https://doi.org/10.1182/blood.2023023568 (gokbuget2024managementofall pages 21-22)
Chemo-free / near chemo-free TKI + blinatumomab for Ph+ ALL (e.g., ponatinib + blinatumomab; dasatinib + blinatumomab)	Dual targeting of BCR::ABL1 signaling plus CD19-directed T-cell cytotoxicity	Frontline Ph+ ALL; increasingly used to reduce/avoid conventional chemotherapy and sometimes HSCT	Ponatinib + blinatumomab (JCO 2024): CMR 83% overall (67% after course 1), NGS-MRD negativity 98%, only 2/60 underwent HSCT, 3-year OS 91%, EFS 77%, median follow-up 24 months (kantarjian2024resultsofthe pages 1-3, kantarjian2024resultsofthe pages 3-4). D-ALBA long-term: 4-year/approximately 53-month DFS 75.8%, OS 80.7%, early molecular responders had no events (kantarjian2024ponatinib‐reviewofhistorical pages 10-11)	CNS relapse remains an issue in chemo-free Ph+ regimens; ponatinib vascular toxicities; blinatumomab CRS/neurotoxicity; transplant role becoming more selective (kantarjian2024resultsofthe pages 3-4, kantarjian2024ponatinib‐reviewofhistorical pages 10-11)	Kantarjian et al., J Clin Oncol (Dec 2024) https://doi.org/10.1200/jco.24.00272 (kantarjian2024resultsofthe pages 1-3); Foà et al., J Clin Oncol (Mar 2024) https://doi.org/10.1200/jco.23.01075 (kantarjian2024ponatinib‐reviewofhistorical pages 10-11)
CAR-T cell therapy (CD19-directed; pediatric and adult B-ALL)	Autologous engineered T cells targeting CD19 on B lymphoblasts	Standard for selected R/R B-ALL; bridge or alternative to HSCT; pediatric/young adult use especially established	2024 treatment reviews state CAR-T is standard in R/R BCP-ALL and has demonstrated major efficacy, but the provided contexts here do not include a single 2024 trial with reportable ORR/OS figures for inclusion (stelljes2024ph−allimmunotherapy pages 1-2, kantarjian2024inotuzumabozogamicinin pages 15-17)	CRS, ICANS, prolonged cytopenias, hypogammaglobulinemia; manufacturing/access/logistics and disease burden at infusion are major real-world constraints; often sequenced with blinatumomab/inotuzumab/HSCT (kantarjian2024inotuzumabozogamicinin pages 15-17, stelljes2024ph−allimmunotherapy pages 1-2)	Stelljes, Hematology (Dec 2024) https://doi.org/10.1182/hematology.2024000531 (stelljes2024ph−allimmunotherapy pages 1-2); Kantarjian et al., Cancer (Aug 2024) https://doi.org/10.1002/cncr.35505 (kantarjian2024inotuzumabozogamicinin pages 15-17)
Allogeneic hematopoietic cell transplantation (allo-HCT)	Graft-versus-leukemia effect after myeloablative or reduced-intensity conditioning	Consolidation for high-risk disease, persistent/recurrent MRD, poor-risk genomics, or selected R/R patients in remission	ELN/expert reviews: MRD is central to transplant selection; poor MRD response supports SCT, whereas deeper MRD responses with TKI/blinatumomab regimens are reducing HSCT use in some Ph+ patients. In ponatinib+blinatumomab 2024 study, only 2 patients underwent HSCT despite 3-year OS 91% (gokbuget2024managementofall pages 6-6, kantarjian2024resultsofthe pages 3-4, gokbuget2024managementofall pages 1-2)	Transplant-related mortality, GVHD, infection, conditioning toxicity; pre-HSCT MRD level strongly predicts relapse; post-inotuzumab VOD/SOS risk requires mitigation (gokbuget2024managementofall pages 6-6, kantarjian2024inotuzumabozogamicinin pages 15-17)	Gökbuget et al., Blood (May 2024) https://doi.org/10.1182/blood.2023023568 (gokbuget2024managementofall pages 6-6); Kantarjian et al., J Clin Oncol (Dec 2024) https://doi.org/10.1200/jco.24.00272 (kantarjian2024resultsofthe pages 3-4)
MRD-directed therapy / response-adapted management	Uses highly sensitive residual leukemia detection (MFC, PCR, NGS) to escalate/de-escalate therapy and determine HSCT need	Cross-cutting strategy in frontline, MRD+, pre-/post-HSCT, and salvage settings	ELN 2024: threshold commonly 0.01% (10^-4); each log MRD increase worsens relapse risk; persistent/recurrent MRD should trigger therapy change; blinatumomab is the pivotal MRD-clearing agent. Review: MFC sensitivity ~10^-5; PCR/HTS up to 10^-6; key timepoints often 6–8 and 10–12 weeks (gokbuget2024managementofall pages 6-6, yoon2024diagnosticandtherapeutic pages 6-8)	Requires experienced reference labs; assay choice affects classification; marrow regeneration can confound flow; MRD does not capture extramedullary disease; low-level MRD may be intermediate-risk and still actionable (gokbuget2024managementofall pages 6-6, yoon2024diagnosticandtherapeutic pages 6-8)	Gökbuget et al., Blood (May 2024) https://doi.org/10.1182/blood.2023023568 (gokbuget2024managementofall pages 6-6); Yoon & Lee, Korean J Intern Med (Jan 2024) https://doi.org/10.3904/kjim.2023.407 (yoon2024diagnosticandtherapeutic pages 6-8)

Table: This table summarizes major modern treatment modalities for acute lymphoblastic leukemia, including frontline, MRD-directed, relapsed/refractory, and transplant strategies. It highlights 2024 efficacy data, implementation considerations, and key sources for rapid evidence-based comparison.

Chemo-free Ph+ ALL: ponatinib + blinatumomab (JCO 2024)

A 2024 JCO trial update reports deep molecular responses with minimal HSCT use: - CMR by RT‑PCR 83% overall; MRD negativity by clono‑sequencing 98% overall; 3‑year OS 91% and EFS 77%; only 2 patients underwent HSCT; median follow-up 24 months. (kantarjian2024resultsofthe pages 1-3, kantarjian2024resultsofthe pages 3-4)

Direct abstract quote: “At a median follow-up of 24 months, the complete molecular response rate … was 83% … and the rate of measurable residual disease negativity … was 98% … The estimated 3-year overall survival rate was 91% and event-free survival rate was 77%.” (kantarjian2024resultsofthe pages 3-4)

Reduced-intensity induction for Ph-negative BCP‑ALL: reduced-dose chemotherapy + blinatumomab (J Hematol Oncol 2024)

Prospective multicenter phase 2 (NCT05557110) results: - After 2 weeks of blinatumomab: CRc 94%, MRD-negative 86%. - With up to 4 weeks: CR 100%, MRD-negative 89%. - 1‑year OS 97.1%, 1‑year PFS 82.2%; follow-up 11.5 months. (lu2024reduceddosechemotherapyand pages 1-2)

Direct abstract quote: “From September 2022 to December 2023, we conducted … (NCT05557110) … 33 (94%) achieved CRc … 30 (86%) achieving measurable residual disease (MRD) negativity … estimated 1-year overall survival and 1-year progression-free survival rates were 97.1% and 82.2%.” (lu2024reduceddosechemotherapyand pages 1-2)

12.3 MRD-directed therapy

ELN 2024 notes persistent/recurrent MRD should prompt therapy change; blinatumomab is highlighted as the pivotal agent tested in a major MRD trial, often converting to molecular remission; many groups use MRD to decide on allo‑HCT. (gokbuget2024managementofall pages 6-6)

12.4 Pharmacogenomics (implementation-relevant)

A 2024 pharmacogenetics review lists key genotype-toxicity associations: - For 6‑mercaptopurine (6‑MP): TPMT (e.g., TPMT2 238G>C; TPMT3B 460G>A; TPMT*3C 719A>G), NUDT15 c.415C>T, and ITPA (94C>A; IVS2+21A>C). (graiqevciuka2024implementationofpharmacogenetics pages 5-7, graiqevciuka2024implementationofpharmacogenetics pages 1-3) - For methotrexate (MTX): MTHFR C677T and A1298C variants are discussed, though the review notes evidence for some MTX markers is inconsistent and highlights SLCO1B1 as a more reliable MTX handling gene in cited literature. (graiqevciuka2024implementationofpharmacogenetics pages 5-7)

12.5 Suggested MAXO terms (examples)

Antineoplastic chemotherapy MAXO:0000746 (approximate; verify exact MAXO ID)
Allogeneic hematopoietic stem cell transplantation MAXO:0000748 (verify)
CAR T-cell therapy MAXO:0001097 (verify)
Targeted therapy / tyrosine kinase inhibitor therapy (verify appropriate MAXO term)
MRD monitoring (diagnostic procedure; may map better to OBI rather than MAXO). (gokbuget2024managementofall pages 6-6)

13. Prevention

13.1 Primary prevention

Because most ALL risk is not attributable to modifiable exposures, there is no established population-level primary prevention strategy. Nevertheless, risk literature motivates research into prenatal/early-life exposures and broader public health reduction of known hazards (e.g., ionizing radiation). (little2024solarultravioletradiation pages 1-2, ekpa2023areviewof pages 2-3)

13.2 Secondary prevention

No general population screening is established. High-risk groups (e.g., strong germline predisposition syndromes) may benefit from specialist surveillance in genetic counseling frameworks; specifics require syndrome-level guidelines (not present in retrieved corpus). (ekpa2023areviewof pages 2-3)

14. Other Species / Natural Disease

Not assessed in the retrieved evidence set.

15. Model Organisms

Not assessed in the retrieved evidence set.

Recent developments and expert analysis (2023–2024)

1) Classification shift to genomics/transcriptomics: ICC and WHO‑HAEM5 explicitly expand genetically and expression-defined entities (including formerly “B‑other”) to improve risk stratification and treatment selection. (duffield2023internationalconsensusclassification pages 1-3, kansal2023diagnosisandmolecular pages 5-7)

2) MRD as a decision engine: ELN 2024 formalizes MRD timing and threshold concepts (commonly 10−4) and embeds MRD into transplant and immunotherapy decisions. (gokbuget2024managementofall pages 6-6, gokbuget2024managementofall pages 1-2)

3) Frontline immunotherapy integration and chemotherapy de-escalation: 2024 trials and reviews show movement of blinatumomab into upfront settings and successful chemo-free Ph+ strategies with high molecular response rates and reduced HSCT utilization. (lu2024reduceddosechemotherapyand pages 1-2, kantarjian2024resultsofthe pages 1-3, sebastian2024howitreat pages 1-2)

Key figure supporting environmental-risk discussion

The relationship between UVR and ALL incidence reported in the 2024 British Journal of Cancer SEER ecological analysis is visually summarized in the retrieved figure. (little2024solarultravioletradiation media 5ae23b8e)

References

(shah2024acutelymphoblasticleukemia pages 1-2): Bijal Shah, Ryan J. Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Michael Haddadin, Nitin Jain, Brian Jonas, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Meixiao Long, Selina Luger, James K. Mangan, Stephanie Massaro, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Caner Saygin, Marc Schwartz, Paul Shami, Benjamin Tomlinson, Jonathan Webster, Ajibola Awotiwon, and Katie Stehman. Acute lymphoblastic leukemia, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22 8:563-576, Oct 2024. URL: https://doi.org/10.6004/jnccn.2024.0051, doi:10.6004/jnccn.2024.0051. This article has 75 citations.
(duffield2023internationalconsensusclassification pages 1-3): Amy S. Duffield, Charles G. Mullighan, and Michael J. Borowitz. International consensus classification of acute lymphoblastic leukemia/lymphoma. Virchows Archiv, 482:11-26, Nov 2023. URL: https://doi.org/10.1007/s00428-022-03448-8, doi:10.1007/s00428-022-03448-8. This article has 226 citations and is from a peer-reviewed journal.
(kansal2023diagnosisandmolecular pages 1-2): Rina Kansal. Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: b-/t-cell acute lymphoblastic leukemias. Lymphatics, 1:118-154, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020011, doi:10.3390/lymphatics1020011. This article has 12 citations.
(kansal2023diagnosisandmolecular pages 5-7): Rina Kansal. Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: b-/t-cell acute lymphoblastic leukemias. Lymphatics, 1:118-154, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020011, doi:10.3390/lymphatics1020011. This article has 12 citations.
(yoon2024diagnosticandtherapeutic pages 1-2): Jae-Ho Yoon and Seok Lee. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy. The Korean Journal of Internal Medicine, 39:34-56, Jan 2024. URL: https://doi.org/10.3904/kjim.2023.407, doi:10.3904/kjim.2023.407. This article has 12 citations and is from a peer-reviewed journal.
(kansal2023diagnosisandmolecular pages 4-5): Rina Kansal. Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: b-/t-cell acute lymphoblastic leukemias. Lymphatics, 1:118-154, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020011, doi:10.3390/lymphatics1020011. This article has 12 citations.
(gokbuget2024managementofall pages 1-2): Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, and Renato Bassan. Management of all in adults: 2024 eln recommendations from a european expert panel. Blood, 143:1903-1930, May 2024. URL: https://doi.org/10.1182/blood.2023023568, doi:10.1182/blood.2023023568. This article has 133 citations and is from a highest quality peer-reviewed journal.
(liu2024epidemiologicalcharacteristicsand pages 1-3): Shuojie Liu, Bin Hu, and Jiaqin Zhang. Epidemiological characteristics and influencing factors of acute leukemia in children and adolescents and adults: a large population-based study. Hematology, Apr 2024. URL: https://doi.org/10.1080/16078454.2024.2327916, doi:10.1080/16078454.2024.2327916. This article has 19 citations and is from a peer-reviewed journal.
(lu2024reduceddosechemotherapyand pages 1-2): Jing Lu, Huiying Qiu, Ying Wang, Xin Zhou, Haiping Dai, Xuzhang Lu, Xiaofei Yang, Bin Gu, Ming Hong, Miao Miao, Ruinan Lu, Jun Wang, Qian Wu, Mengxing Xue, Yun Wang, Ailing Deng, Yaoyao Shen, Yin Liu, Xueqing Dou, Yutian Lei, Depei Wu, Yu Zhu, and Suning Chen. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed ph-negative b-cell precursor acute lymphoblastic leukemia: a phase 2 trial. Journal of Hematology & Oncology, Sep 2024. URL: https://doi.org/10.1186/s13045-024-01597-8, doi:10.1186/s13045-024-01597-8. This article has 17 citations and is from a domain leading peer-reviewed journal.
(kantarjian2024resultsofthe pages 1-3): Hagop Kantarjian, Nicholas J. Short, Fadi G. Haddad, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas C. Issa, Rebecca Garris, Cedric Nasnas, Lewis Nasr, Farhad Ravandi, and Elias Jabbour. Results of the simultaneous combination of ponatinib and blinatumomab in philadelphia chromosome-positive all. Journal of Clinical Oncology, 42:4246-4251, Dec 2024. URL: https://doi.org/10.1200/jco.24.00272, doi:10.1200/jco.24.00272. This article has 80 citations and is from a highest quality peer-reviewed journal.
(ekpa2023areviewof pages 2-3): Queen L Ekpa, Prince C Akahara, Alexis M Anderson, Omowunmi O Adekoya, Olamide O Ajayi, Peace O Alabi, Okelue E Okobi, Oluwadamilola Jaiyeola, and Medara S Ekanem. A review of acute lymphocytic leukemia (all) in the pediatric population: evaluating current trends and changes in guidelines in the past decade. Cureus, Dec 2023. URL: https://doi.org/10.7759/cureus.49930, doi:10.7759/cureus.49930. This article has 49 citations.
(little2024solarultravioletradiation pages 1-2): Mark P. Little, Jim Z. Mai, Michelle Fang, Pavel Chernyavskiy, Victoria Kennerley, Elizabeth K. Cahoon, Myles G. Cockburn, Gerald M. Kendall, and Michael G. Kimlin. Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-hodgkin lymphoma in a us population-based dataset. British Journal of Cancer, 130:1441-1452, Feb 2024. URL: https://doi.org/10.1038/s41416-024-02629-3, doi:10.1038/s41416-024-02629-3. This article has 15 citations and is from a domain leading peer-reviewed journal.
(little2024solarultravioletradiation pages 8-9): Mark P. Little, Jim Z. Mai, Michelle Fang, Pavel Chernyavskiy, Victoria Kennerley, Elizabeth K. Cahoon, Myles G. Cockburn, Gerald M. Kendall, and Michael G. Kimlin. Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-hodgkin lymphoma in a us population-based dataset. British Journal of Cancer, 130:1441-1452, Feb 2024. URL: https://doi.org/10.1038/s41416-024-02629-3, doi:10.1038/s41416-024-02629-3. This article has 15 citations and is from a domain leading peer-reviewed journal.
(little2024solarultravioletradiation media 5ae23b8e): Mark P. Little, Jim Z. Mai, Michelle Fang, Pavel Chernyavskiy, Victoria Kennerley, Elizabeth K. Cahoon, Myles G. Cockburn, Gerald M. Kendall, and Michael G. Kimlin. Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-hodgkin lymphoma in a us population-based dataset. British Journal of Cancer, 130:1441-1452, Feb 2024. URL: https://doi.org/10.1038/s41416-024-02629-3, doi:10.1038/s41416-024-02629-3. This article has 15 citations and is from a domain leading peer-reviewed journal.
(johnston2024socioeconomicdeterminantsof pages 1-2): Hannah Johnston, Hamed Rahmani Youshanlouei, Clinton Osei, Anand A. Patel, Adam DuVall, Peng Wang, Pankhuri Wanjari, Jeremy Segal, Girish Venkataraman, Jason X. Cheng, Sandeep Gurbuxani, Angela Lager, Carrie Fitzpatrick, Michael Thirman, Mariam Nawas, Hongtao Liu, Michael Drazer, Olatoyosi Odenike, Richard Larson, Wendy Stock, and Caner Saygin. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Advances, 8:164-171, Dec 2024. URL: https://doi.org/10.1182/bloodadvances.2023011862, doi:10.1182/bloodadvances.2023011862. This article has 11 citations and is from a peer-reviewed journal.
(karim2023diagnosticclueof pages 2-4): MA Karim, N Yesmin, and M Begum. Diagnostic clue of acute lymphoblastic leukemia for frontline clinicians from clinicopathological features: study of 223 cases of in a tertiary care hospital from …. Unknown journal, 2023.
(talukder2024acutelymphoblasticleukemia pages 1-3): Manik Kumar Talukder, Kamrul Laila, Md. Arif Hossain, Md. Shafiqul Islam, Md. Zahidul Islam, Kalyan Benjamin Gomes, Mujammel Haque, Md. Mahbubul Islam, and Md. Imnul Islam. Acute lymphoblastic leukemia presenting as systemic juvenile idiopathic arthritis: experience from bangladesh. Open Journal of Rheumatology and Autoimmune Diseases, 14:1-12, Jan 2024. URL: https://doi.org/10.4236/ojra.2024.141001, doi:10.4236/ojra.2024.141001. This article has 1 citations.
(karim2023diagnosticclueof pages 5-6): MA Karim, N Yesmin, and M Begum. Diagnostic clue of acute lymphoblastic leukemia for frontline clinicians from clinicopathological features: study of 223 cases of in a tertiary care hospital from …. Unknown journal, 2023.
(karim2023diagnosticclueof pages 1-2): MA Karim, N Yesmin, and M Begum. Diagnostic clue of acute lymphoblastic leukemia for frontline clinicians from clinicopathological features: study of 223 cases of in a tertiary care hospital from …. Unknown journal, 2023.
(little2024solarultravioletradiation pages 11-11): Mark P. Little, Jim Z. Mai, Michelle Fang, Pavel Chernyavskiy, Victoria Kennerley, Elizabeth K. Cahoon, Myles G. Cockburn, Gerald M. Kendall, and Michael G. Kimlin. Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-hodgkin lymphoma in a us population-based dataset. British Journal of Cancer, 130:1441-1452, Feb 2024. URL: https://doi.org/10.1038/s41416-024-02629-3, doi:10.1038/s41416-024-02629-3. This article has 15 citations and is from a domain leading peer-reviewed journal.
(kantarjian2024ponatinib‐reviewofhistorical pages 10-11): Hagop M. Kantarjian, Helen T. Chifotides, Fadi G. Haddad, Nicholas J. Short, Sanam Loghavi, and Elias Jabbour. Ponatinib‐review of historical development, current status, and future research. American Journal of Hematology, 99:1576-1585, May 2024. URL: https://doi.org/10.1002/ajh.27355, doi:10.1002/ajh.27355. This article has 25 citations and is from a domain leading peer-reviewed journal.
(gokbuget2024managementofall pages 6-6): Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, and Renato Bassan. Management of all in adults: 2024 eln recommendations from a european expert panel. Blood, 143:1903-1930, May 2024. URL: https://doi.org/10.1182/blood.2023023568, doi:10.1182/blood.2023023568. This article has 133 citations and is from a highest quality peer-reviewed journal.
(sebastian2024howitreat pages 1-2): Giebel Sebastian. How i treat newly diagnosed acute lymphoblastic leukemia. Clinical Hematology International, 6:51-61, May 2024. URL: https://doi.org/10.46989/001c.117026, doi:10.46989/001c.117026. This article has 8 citations.
(yoon2024diagnosticandtherapeutic pages 6-8): Jae-Ho Yoon and Seok Lee. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy. The Korean Journal of Internal Medicine, 39:34-56, Jan 2024. URL: https://doi.org/10.3904/kjim.2023.407, doi:10.3904/kjim.2023.407. This article has 12 citations and is from a peer-reviewed journal.
(shah2024acutelymphoblasticleukemia pages 3-5): Bijal Shah, Ryan J. Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Michael Haddadin, Nitin Jain, Brian Jonas, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Meixiao Long, Selina Luger, James K. Mangan, Stephanie Massaro, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Caner Saygin, Marc Schwartz, Paul Shami, Benjamin Tomlinson, Jonathan Webster, Ajibola Awotiwon, and Katie Stehman. Acute lymphoblastic leukemia, version 2.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22 8:563-576, Oct 2024. URL: https://doi.org/10.6004/jnccn.2024.0051, doi:10.6004/jnccn.2024.0051. This article has 75 citations.
(ghosh2024incidenceandsurvivability pages 1-3): Ishan Ghosh and Sudipto Mukherjee. Incidence and survivability of acute lymphocytic leukemia patients in the united states: analysis of seer data set from 2000-2019. Journal of Cancer Therapy, 15:141-163, Jan 2024. URL: https://doi.org/10.4236/jct.2024.154014, doi:10.4236/jct.2024.154014. This article has 0 citations.
(stelljes2024ph−allimmunotherapy pages 1-2): Matthias Stelljes. Ph− all: immunotherapy in upfront treatment. Hematology, 2024:86-92, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000531, doi:10.1182/hematology.2024000531. This article has 1 citations and is from a peer-reviewed journal.
(sebastian2024howitreat pages 5-7): Giebel Sebastian. How i treat newly diagnosed acute lymphoblastic leukemia. Clinical Hematology International, 6:51-61, May 2024. URL: https://doi.org/10.46989/001c.117026, doi:10.46989/001c.117026. This article has 8 citations.
(kantarjian2024inotuzumabozogamicinin pages 15-17): Hagop M. Kantarjian, Nicolas Boissel, Cristina Papayannidis, Marlise R. Luskin, Matthias Stelljes, Anjali S. Advani, Elias J. Jabbour, Josep‐Maria Ribera, and David I. Marks. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions. Cancer, 130:3631-3646, Aug 2024. URL: https://doi.org/10.1002/cncr.35505, doi:10.1002/cncr.35505. This article has 16 citations and is from a domain leading peer-reviewed journal.
(gokbuget2024managementofall pages 21-22): Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, and Renato Bassan. Management of all in adults: 2024 eln recommendations from a european expert panel. Blood, 143:1903-1930, May 2024. URL: https://doi.org/10.1182/blood.2023023568, doi:10.1182/blood.2023023568. This article has 133 citations and is from a highest quality peer-reviewed journal.
(kantarjian2024resultsofthe pages 3-4): Hagop Kantarjian, Nicholas J. Short, Fadi G. Haddad, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas C. Issa, Rebecca Garris, Cedric Nasnas, Lewis Nasr, Farhad Ravandi, and Elias Jabbour. Results of the simultaneous combination of ponatinib and blinatumomab in philadelphia chromosome-positive all. Journal of Clinical Oncology, 42:4246-4251, Dec 2024. URL: https://doi.org/10.1200/jco.24.00272, doi:10.1200/jco.24.00272. This article has 80 citations and is from a highest quality peer-reviewed journal.
(graiqevciuka2024implementationofpharmacogenetics pages 5-7): Violeta Graiqevci-Uka, Emir Behluli, Rifat Hadziselimovic, Thomas Liehr, and Gazmend Temaj. Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia. Research Results in Pharmacology, 10:27-39, Jun 2024. URL: https://doi.org/10.18413/rrpharmacology.10.382, doi:10.18413/rrpharmacology.10.382. This article has 2 citations.
(graiqevciuka2024implementationofpharmacogenetics pages 1-3): Violeta Graiqevci-Uka, Emir Behluli, Rifat Hadziselimovic, Thomas Liehr, and Gazmend Temaj. Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia. Research Results in Pharmacology, 10:27-39, Jun 2024. URL: https://doi.org/10.18413/rrpharmacology.10.382, doi:10.18413/rrpharmacology.10.382. This article has 2 citations.

Artifacts

Edison artifact artifact-00

Acute Lymphoblastic Leukemia Deep Research Fallback ▸

Acute Lymphoblastic Leukemia Deep Research Fallback

Provider Attempts

2026-05-08T13:00Z: just research-disorder asta Acute_Lymphoblastic_Leukemia failed: agentapi not found in PATH and no provider API keys configured (OPENAI_API_KEY, EDISON_API_KEY, ASTA_API_KEY, PERPLEXITY_API_KEY all unset in this environment).
2026-05-08T13:00Z: just research-disorder openai Acute_Lymphoblastic_Leukemia failed for the same reason.
2026-05-08T13:00Z: just research-disorder perplexity Acute_Lymphoblastic_Leukemia failed for the same reason.
2026-05-08T13:00Z: just research-disorder falcon Acute_Lymphoblastic_Leukemia failed for the same reason.

No provider-generated research artifact was available to integrate. Curation therefore proceeded from previously fetched PubMed abstracts and full-text caches in references_cache/, without hand-editing any cache files.

Evidence Scope Used For Curation

PMID:23523389 (Inaba H, Greaves M, Mullighan CG. Lancet 2013) — comprehensive Lancet Seminar review on ALL biology, genetics, treatment, and outcomes. Used to anchor:
founding-lesion model (genome-wide profiling, recurrent translocations and aneuploidy)
prenatal/in-utero initiation language for the "Acquisition of Initiating Genetic Lesion" pathophysiology node
differentiation block (PAX5, IKZF1, EBF1 alterations in >2/3 of B-ALL)
bone marrow failure (induction therapy "restores normal haematopoiesis")
Ph-like / BCR-ABL1-like ALL subtype definition (10-12% of B-ALL, BCR-ABL1-negative, IKZF1-altered, poor outcome)
PMID:15472075 (Weng AP et al. Science 2004) — the landmark NOTCH1 paper, used to anchor activating NOTCH1 mutations as the dominant driver in T-ALL (>50% of cases).
PMID:19129520 (Mullighan CG et al. NEJM 2009) — IKZF1 deletion as an independent predictor of poor outcome in B-cell ALL.
PMID:41251904 (recent Ph+ ALL review) — used to anchor the BCR-ABL1 fusion defining the Ph+ ALL subtype.

Curation Conclusions

The accepted disease model for ALL is a multi-step transformation in which a founding cytogenetic lesion (translocation creating a chimeric oncogene or aneuploidy) is acquired in a B- or T-lymphoid progenitor — often in utero in B-ALL — followed by acquisition of cooperating mutations that: - corrupt lymphoid transcriptional programs (chimeric TFs; KMT2A-driven HOXA upregulation; NOTCH1 in T-ALL) - block differentiation (IKZF1, PAX5, EBF1 lesions in B-ALL; CDKN2A/B loss most prominent in T-ALL) - drive constitutive proliferation/survival signaling (BCR-ABL1 RAS/PI3K/JAK, NOTCH1-MYC, KMT2A-HOXA9/MEIS1)

The clonal lymphoblast population then expands in the marrow and disseminates to extramedullary sites, producing two dominant clinical axes: 1. Bone marrow failure with pancytopenia (anemia, bleeding from thrombocytopenia, infections from neutropenia) 2. Extramedullary disease (lymphadenopathy, hepatosplenomegaly, anterior mediastinal mass in T-ALL, CNS infiltration as a sanctuary site).

Risk stratification, treatment choice (TKIs in Ph+ and Ph-like ALL, JAK inhibitors in CRLF2-rearranged disease, blinatumomab/inotuzumab/CAR-T in relapsed B-ALL, allogeneic HSCT for highest-risk groups), and prognosis are governed largely by molecular subtype and MRD response.

Subtypes

Curated subtypes in the YAML: - B-ALL with ETV6-RUNX1 (favorable) - B-ALL with TCF3-PBX1 (intermediate, historical CNS relapse risk) - B-ALL with KMT2A rearrangement (high-risk; infant-predominant) - Ph+ ALL (BCR-ABL1) (TKI-targetable) - Ph-like ALL (BCR-ABL1-like) (high-risk; kinase-rearranged; partly TKI/JAK-targetable) - T-ALL (NOTCH1-driven; mediastinal mass; ETP-ALL subset)

Items Intentionally Skipped

icdo_morphology was left as the broad "Leukemia" classification because splitting into subtype-specific codes (e.g., 9811/3 B-ALL NOS, 9837/3 T-ALL) on a parent disorder would require either duplicating the parent or moving the field per subtype. Worth revisiting if ICDO subtyping at the subtype level is later added to the schema.
Each fusion genetic entry was given a single canonical gene_term (the more clinically central partner: ABL1 for BCR-ABL1, RUNX1 for ETV6-RUNX1, PBX1 for TCF3-PBX1). The gene_term slot is single-valued, so the second partner is documented inline in notes with its hgnc: ID for traceability.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Differential Diagnoses

Related Datasets

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 Concise overview

1.2 Synonyms / alternative names

1.3 Evidence provenance

2. Etiology

2.1 Disease causal factors (current understanding)

2.2 Risk factors

Genetic susceptibility / predisposition

Environmental and demographic risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Common presenting symptoms/signs (human clinical)

3.2 Laboratory abnormalities (human clinical)

3.3 Suggested HPO terms (examples)

3.4 Quality of life impact

4. Genetic / Molecular Information

4.1 Core disease genes and recurrent abnormalities (somatic)

4.2 Germline predisposition genes (examples)

4.3 Epigenetics

5. Environmental Information

5.1 Environmental factors

5.2 Lifestyle factors

5.3 Infectious agents

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

6.2 Pathway-level themes (from subtype concepts)

6.3 Suggested GO / CL terms (examples)

7. Anatomical Structures Affected

7.1 Organ/tissue level

7.2 Suggested UBERON terms (examples)

8. Temporal Development

8.1 Onset

8.2 Progression and course

9. Inheritance and Population

9.1 Epidemiology (recent statistics)

9.2 Heritability/inheritance

10. Diagnostics

10.1 Core diagnostic modalities

10.2 MRD (measurable/minimal residual disease): methods, thresholds, timing

10.3 Guideline risk criteria examples

11. Outcome / Prognosis

11.1 Survival highlights (recent/referenced)

11.2 Prognostic factors (examples)

12. Treatment

12.1 Current applications and real-world implementation (2024 consensus)

12.2 Key modalities, evidence, and 2024 trial statistics

Chemo-free Ph+ ALL: ponatinib + blinatumomab (JCO 2024)

Reduced-intensity induction for Ph-negative BCP‑ALL: reduced-dose chemotherapy + blinatumomab (J Hematol Oncol 2024)

12.3 MRD-directed therapy

12.4 Pharmacogenomics (implementation-relevant)

12.5 Suggested MAXO terms (examples)

13. Prevention

13.1 Primary prevention

13.2 Secondary prevention

14. Other Species / Natural Disease

15. Model Organisms

Recent developments and expert analysis (2023–2024)

Key figure supporting environmental-risk discussion

Artifacts

Acute Lymphoblastic Leukemia Deep Research Fallback

Provider Attempts

Evidence Scope Used For Curation

Curation Conclusions